


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update July 6 - July 12, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 28 2020 734 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

[Why the Covid-19 financial crisis will leave lasting scars on Gen Z \(Guardian\)](#)

[WHO underplaying risk of airborne spread of Covid-19, say scientists \(Guardian\)](#)

Scientists investigate cases of post-Covid-19 fatigue (Guardian)
As the Virus Surged, Florida Partied. Tracking the Revelers Has Been Tough. (NYT)
Mexico border towns try to stop Americans crossing.(Guardian)
Serious brain disorders in people with mild coronavirus symptoms (Guardian)
Global report: Tokyo hits Covid-19 high as Australia limits arrivals (Guardian)
Over 40 Florida hospitals max out ICU capacity.(Guardian)
Coronavirus in Pregnant Women Finds Striking Racial Differences (NYT)
Study of 17 Million Identifies Crucial Risk Factors for Coronavirus Deaths.(NYT)
American Horror, Starring Donald Trump (NYT)
A Health Worker Raised Alarms About the Coronavirus. Then He Lost His Job.(NYT)
The Virus and an E.R. Doctor's Suicide (NYT)
Proton pump inhibitor use doubles risk for COVID-19 (Healio)
Why We Still Don't Know Enough About Covid-19 and Pregnancy.(NYT)
How ICE Helped Spread the Coronavirus (NYT)

Key Articles

1. **Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.** JAMA 2020; Wiersinga WJ, Rhodes A, Cheng AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648899>
2. **Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.** Int J Infect Dis 2020; Sun M, Xu Y, He H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634589>
3. **Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.** Clin Infect Dis 2020; Oussalah A, Gleye S, Clerc Urmes I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623470>
4. **Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020.** Euro Surveill 2020; Vestergaard LS, Nielsen J, Richter L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643601>
5. **COVID-19 Impact on People with Diabetes in the South and Central America.** Diabetes Res Clin Pract 2020;108301 Thomaz Ugliara Barone M, Villarroel D, Vieira de Luca P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623036>
6. **The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting.** Int J Gynaecol Obstet 2020; Takemoto MLS, Menezes MO, Andreucci CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644220>

7. **Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?** JAMA Netw Open 2020; 3:e2013556Rabbani AB, Parikh RV, Rafique AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579190>
8. **Association of diabetes and hypertension with disease severity in covid-19 patients: a systematic literature review and exploratory meta-analysis.** Diabetes Res Clin Pract 2020:108295Parveen R, Sehar N, Bajpai R, Bharal Agarwal N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623032>
9. **Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events.** Diabetes Metab Syndr 2020; 14:1017-1025Nandy K, Salunke A, Pathak SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634716>
10. **Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.** Reprod. Biomed. Online 2020; La Marca A, Capuzzo M, Paglia T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651106>
11. **Diabetes and COVID-19: Global and Regional Perspectives.** Diabetes Res Clin Pract 2020:108303Jeong IK, Ho Yoon K, Kyu Lee M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623038>
12. **BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).** Proc Natl Acad Sci U S A 2020; Escobar LE, Molina-Cruz A, Barillas-Mury C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647056>
13. **Kidney Involvement in COVID-19: Need for Better Definitions.** J Am Soc Nephrol 2020; Delsante M, Rossi GM, Gandolfini I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646857>
14. **Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.** JAMA Netw Open 2020; 3:e2013136Deftereos SG, Giannopoulos G, Vrachatis DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579195>
15. **A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity.** Arch Pathol Lab Med 2020; Aloisio E, Chibireva M, Serafini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649222>

Basic Science (27 articles)

1. **Research on COVID-19 based on ARIMA model(Delta)-Taking Hubei, China as an example to see the epidemic in Italy.** J Infect Public Health 2020; Yang Q, Wang J, Ma H, Wang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624404>

2. **Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus.** Cell. Mol. Neurobiol. 2020; Xu J, Lazartigues E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623546>
3. **Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients.** Clin Infect Dis 2020; Wong YC, Lau SY, Wang To KK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649739>
4. **Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response.** Genes (Basel) 2020; 11Vishnubalaji R, Shaath H, Alajez NM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646047>
5. **Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.** Drug Dev Res 2020; Sohag AAM, Hannan MA, Rahman S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632960>
6. **Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.** Curr. Stem Cell Res. Ther. 2020; Richard SA, Kampo S, Sackey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628591>
7. **Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.** Vaccine 2020; Ren W, Sun H, Gao GF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651113>
8. **Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.** Pharmaceuticals (Basel) 2020; 13Palmeira A, Sousa E, Koseler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630514>
9. **Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.** Indian J. Clin. Biochem. 2020; 35:274-284Pal A, Pawar A, Goswami K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641874>
10. **Application of Artificial Intelligence in COVID-19 drug repurposing.** Diabetes Metab Syndr 2020; 14:1027-1031Mohanty S, Harun Ai Rashid M, Mridul M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634717>
11. **Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.** Cell. Mol. Life Sci. 2020; Mercurio I, Tragni V, Busto F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623480>
12. **An update on origin of SARS-CoV-2: Despite closest identity, bat (RaTG13) and Pangolin derived Coronaviruses varied in the critical binding site and O-linked glycan residues.** J Med Virol 2020; Malaiyan J, Arumugam S, Mohan K, Radhakrishnan GG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633815>
13. **Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.** Cardiovasc Res 2020; Liu H, Gai S, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638018>
14. **Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2.** J Cell Mol Med 2020; Li Y, Xu Q, Ma L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639084>
15. **SARS-CoV-2 host diversity: An update of natural infections and experimental evidence.** J Microbiol Immunol Infect 2020; Hossain MG, Javed A, Akter S, Saha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624360>
16. **Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.** J Allergy Clin Immunol 2020; Hosoki K, Chakraborty A, Sur S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624257>
17. **SARS-CoV2 envelope protein: Non-synonymous mutations and its consequences.** Genomics 2020; Hassan SS, Choudhury PP, Roy B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640274>
18. **The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.** Cytokine Growth Factor Rev. 2020; Goker Bagca B, Biray Avci C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636055>
19. **In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.** Chin J Integr Med 2020; 26:527-532Gao LQ, Xu J, Chen SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632717>
20. **On the potential role of exosomes in the COVID-19 reinfection/reactivation opportunity.** J Biomol Struct Dyn 2020:1-12Elrashdy F, Aljaddawi AA, Redwan EM, Uversky VN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643586>
21. **Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.** Proc Natl Acad Sci U S A 2020; Dawadi S, Simmons N, Miklossy G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641511>
22. **SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.** Theranostics 2020; 10:7448-7464Datta PK, Liu F, Fischer T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642005>
23. **Canonical and Noncanonical Autophagy as Potential Targets for COVID-19.** Cells 2020; 9Bello-Perez M, Sola I, Novoa B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635598>
24. **Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.** Cell 2020; Barnes CO, West AP, Jr., Huey-Tubman KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645326>
25. **Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.** J Transl Med 2020; 18:281Banerjee A, Santra D, Maiti S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650788>
26. **COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.** Adv. Exp. Med. Biol. 2020; Akkoc T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648245>
27. **Evidence for SARS-CoV-2 Infection of Animal Hosts.** Pathogens 2020; 9Abdel-Moneim AS, Abdelwhab EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629960>

Biomarkers - Genetics (62 articles)

1. **Thrombocytopenia in pregnancy: the importance of differential diagnosis during the COVID-19 pandemic.** J Matern Fetal Neonatal Med 2020:1-3Zitiello A, Grant GE, Ben Ali N, Feki A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643469>

2. **Changes in RT-PCR test results and symptoms during the menstrual cycle of female individuals infected with SARS-CoV-2: report of two cases.** *J Med Virol* 2020; Zheng H, Tan J, Ma K, Meng W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639581>
3. **Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis.** *Eur J Clin Microbiol Infect Dis* 2020; Zhao K, Li R, Wu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651736>
4. **Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Zhang Y, Cao W, Jiang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648093>
5. **Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU.** *Clin Chim Acta* 2020; Zhang D, Zhou X, Yan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645391>
6. **An overview of the genetic variations of the SARS-CoV-2 genomes isolated in Southeast Asian countries.** *J Microbiol Biotechnol* 2020; Yap PSX, Tan TS, Chan YF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627759>
7. **The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide.** *Virus Res.* 2020:198089Yamasaki Y, Ooka S, Tsuchida T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629085>
8. **SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype.** *Gene* 2020:144944Yamamoto N, Ariumi Y, Nishida N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628976>
9. **Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia.** *Respir Res* 2020; 21:171Wu MY, Yao L, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631317>
10. **Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.** *J Clin Virol* 2020; 129:104540Weidner L, Gansdorfer S, Unterweger S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652475>
11. **Time-dependent changes in the clinical characteristics and prognosis of hospitalized COVID-19 patients in Wuhan, China: A retrospective study.** *Clin Chim Acta* 2020; Wang M, Zhang J, Ye D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645392>
12. **Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load.** *Front Med (Lausanne)* 2020; 7:334Wang H, Liu Q, Hu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626720>
13. **Evaluation of seven commercial SARS-CoV-2 RNA detection kits based on real-time polymerase chain reaction (PCR) in China.** *Clin Chem Lab Med* 2020; Wang B, Hu M, Ren Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651975>
14. **SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age.** *Amino Acids* 2020; Vuille-Dit-Bille RN, Liechty KW, Verrey F, Guglielmetti LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627059>
15. **Evaluation of the RealStar(R) SARS-CoV-2 RT-PCR kit RUO performances and limit of detection.** *J Clin Virol* 2020; 129:104520Visseaux B, Le Hingrat Q, Collin G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652476>
16. **Importance of corneal organ culture in donors with possible SARS-CoV-2 infections.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Thaler S, Schindler M, Iftner T *et al.*
17. **Serologic Detection of Latent SARS-CoV-2 Infections in Hemodialysis Centers: A Multi-center, Retrospective Study in Wuhan, China.** *Am J Kidney Dis* 2020; Tang H, Tian JB, Dong JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628990>
18. **Comparison of clinical and microbiological diagnoses for older adults with COVID-19 in Wuhan: a retrospective study.** *Aging Clin. Exp. Res.* 2020; Sun H, Ning R, Tao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638344>
19. **Analysis of ACE2 Genetic Variability among Populations Highlights a Possible Link with COVID-19-Related Neurological Complications.** *Genes (Basel)* 2020; 11Strafella C, Caputo V, Termine A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635188>
20. **Can SARS-CoV-2 infect the eye?-An overview of the receptor status in ocular tissue.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Schnichels S, Rohrbach JM, Bayyoud T *et al.*
21. **Cardiac biomarkers and COVID-19 - Phenotypes and Interpretation.** *Deutsche Medizinische Wochenschrift* 2020; 145:755-760Salbach C, Giannitsis E.
22. **Molecular Aspects of COVID-19 Differential Pathogenesis.** *Pathogens* 2020; 9Rothan HA, Acharya A, Reid SP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640525>
23. **How to perform a nasopharyngeal swab in adults and children in the COVID-19 era.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Pondaven-Letourmy S, Alvin F, Boumghit Y, Simon F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646750>
24. **Development and Evaluation of a duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions.** *Viruses* 2020; 12Pezzi L, Charrel RN, Ninove L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630601>
25. **Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?** *Viruses* 2020; 12Pastorino B, Touret F, Gilles M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646015>
26. **Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.** *Diagn. Microbiol. Infect. Dis.* 2020; 98:115094Ortiz-Prado E, Simbana-Rivera K, Gomez-Barreno L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623267>
27. **The use of radiological imaging alongside reverse transcriptase PCR in diagnosing novel coronavirus disease 2019: a narrative review.** *Future Microbiol.* 2020; Naguib M, Moustafa F, Salman MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638613>
28. **Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients.** *Med. Intensiva* 2020; Moreno G, Carbonell R, Bodi M, Rodriguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646669>

29. **Hematological manifestations of COVID-19.** Leuk. Lymphoma 2020;1-9Mina A, Besien KV, Platanius LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643489>
30. **Lack of sensitivity of an IVD/CE-labeled kit targeting the S gene for detection of SARS-CoV-2.** Clin Microbiol Infect 2020; Matzkies LM, Leitner E, Stelzl E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652240>
31. **Point-of-Care Diagnostic Services as an Integral Part of Health Services during the Novel Coronavirus 2019 Era.** Diagnostics (Basel) 2020; 10Mashamba-Thompson TP, Drain PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635234>
32. **Comparative in silico design and validation of GPS CoVID-19 dtec-RT-qPCR Test.** J. Appl. Microbiol. 2020; Martinez-Murcia A, Bru G, Navarro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652813>
33. **Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China.** Aging (Albany NY) 2020; 12Liu X, Zheng X, Liu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628642>
34. **Prevalence and predictive value of hypocalcemia in severe COVID-19 patients.** J Infect Public Health 2020; Liu J, Han P, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622796>
35. **Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2.** J Cell Mol Med 2020; Li Y, Xu Q, Ma L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639084>
36. **Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19.** J Med Virol 2020; Li TZ, Cao ZH, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644223>
37. **What is the importance of the conjunctiva as a potential transmission pathway for SARS-CoV-2 infections?** Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2020; Lange C, Wolf J, Auw-Haedrich C *et al.*
38. **Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.** Reprod. Biomed. Online 2020; La Marca A, Capuzzo M, Paglia T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651106>
39. **Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19.** Front Cell Infect Microbiol 2020; 10:331Jiang M, Pan W, Arasther A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626666>
40. **The determination of release from isolation of COVID-19 patients requires ultra-high sensitivity nucleic acid test technology.** J Infect 2020; Huang W, Lin D, Wang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622906>
41. **Assessment of SARS-CoV-2 in human semen-a cohort study.** Fertil. Steril. 2020; Holtmann N, Edimiris P, Andree M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650948>
42. **Double-quencher probes improve detection sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a reverse-transcription polymerase chain reaction (RT-PCR) assay.** J. Virol. Methods 2020:113926Hirotsu Y, Mochizuki H, Omata M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650037>
43. **Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study.** Br. J. Haematol. 2020; Hengeveld PJ, Omar Khader A, de Bruin LHA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652585>
44. **Severe refractory thrombocytopenia in a woman positive for coronavirus disease 2019 with lupus and antiphospholipid syndrome.** Lupus 2020;961203320940389Hayden A, Vyas-Lahar A, Rella V, Rudinskaya A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640936>
45. **Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples.** Clin Chim Acta 2020; Haselmann V, Kittel M, Gerhards C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652161>
46. **Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study.** Aging (Albany NY) 2020; 12:11245-11258Han Y, Zhang H, Mu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633729>
47. **COVID-19 Serological Tests: How Well Do They Actually Perform?** Diagnostics (Basel) 2020; 10Ghaffari A, Meurant R, Ardakani A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635444>
48. **Leucocyte Subsets Effectively Predict the Clinical Outcome of Patients With COVID-19 Pneumonia: A Retrospective Case-Control Study.** Front Public Health 2020; 8:299Gan J, Li J, Li S, Yang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626680>
49. **Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.** Kidney Int 2020; Gade AR, Alavala H, Allam SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650019>
50. **Dynamic changes of peripheral blood lymphocytes subsets in adult patients with COVID-19.** Int J Infect Dis 2020; Deng Z, Zhang M, Zhu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634585>
51. **Comparison of the diagnostic performance with whole blood and plasma of four rapid antibody tests for SARS-CoV-2.** Clin Chem Lab Med 2020; Decru B, Van Elslande J, Weemaes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628628>
52. **Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits.** J Clin Virol 2020; 129:104519Chu AW, Chan WM, Ip JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629187>
53. **Predictors of progression from moderate to severe COVID-19: a retrospective cohort.** Clin Microbiol Infect 2020; Cheng B, Hu J, Zuo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622952>
54. **COVID-19 Clinical Diagnostics and Testing Technology.** Pharmacotherapy 2020; Chau CH, Strophe JD, Figg WD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643218>
55. **Testing COVID-19 tests faces methodological challenges.** J. Clin. Epidemiol. 2020; Bossuyt PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622902>
56. **Rapid Large-Scale COVID-19 Testing During Shortages.** Diagnostics (Basel) 2020; 10Beetz C, Skrahina V, Forster TM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650631>
57. **First results of investigations of SARS-CoV-2 RNA in human corneal tissue.** Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2020; Bayyoud T, Iftner T, Bartz-Schmidt KU *et al.*
58. **Absence of Severe Acute Respiratory Syndrome-Coronavirus-2 RNA in ocular tissues.** Am J Ophthalmol Case Rep 2020; 19:100805Bayyoud T, Iftner A, Iftner T *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637738>
59. **Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV.** *J Clin Virol* 2020; 129:104521 Ayouba A, Thaurignac G, Morquin D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623350>
 60. **ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS.** *Am J Pathol* 2020; Argyropoulos KV, Serrano A, Hu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628931>
 61. **A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity.** *Arch Pathol Lab Med* 2020; Aloisio E, Chibireva M, Serafini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649222>
 62. **Road toward rapid-molecular point of care test to detect novel SARS-coronavirus 2019 (COVID-19): Review from updated literature.** *Allergol. Immunopathol. (Madr.)* 2020; Ahmad S, Ali N, Kausar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636083>

Children (19 articles)

1. **COVID-19 Epidemic: Clinical Characteristics of Patients in Pediatric Isolation Ward.** *Clin. Pediatr. (Phila.)* 2020:9922820941228 Zhu J, Wu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646234>
2. **Household Transmission of SARS-CoV-2 from Adults to Children.** *J. Pediatr.* 2020; Yung CF, Kam KQ, Chong CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634405>
3. **How Much May COVID-19 School Closures Increase Childhood Obesity?** *Obesity (Silver Spring)* 2020; Workman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640077>
4. **SARS-CoV-2 Infection in Febrile Neonates.** *J Pediatric Infect Dis Soc* 2020; Wardell H, Campbell JI, VanderPluym C, Dixit A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645175>
5. **Implementation of Home-Based Telemental Health in a Large Child Psychiatry Department During the COVID-19 Crisis.** *J. Child Adolesc. Psychopharmacol.* 2020; Sharma A, Sasser T, Schoenfelder Gonzalez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639849>
6. **COVID-19 in Italian pediatric patients: the experience of a tertiary children's hospital.** *Acta Paediatr* 2020; Romani L, Chiurciu S, Santilli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640088>
7. **Operation of ultrasonography services in a dedicated paediatric hospital and a university hospital in Greece under the COVID-19 pandemic.** *Pediatr Radiol* 2020; Raissaki M, Vakaki M, Kotziamanis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638053>
8. **The paediatric weight management office visit via telemedicine: pre- to post-COVID-19 pandemic.** *Pediatr. Obes.* 2020; O'Hara VM, Johnston SV, Browne NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627434>
9. **Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management.** *Children (Basel)* 2020; 7:Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630212>
10. **COVID-19 Pandemic: Perspective from Italian Pediatric Emergency Physicians.** *Disaster Med Public Health Prep* 2020:1-11 Monzani A, Ragazzoni L, Della Corte F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624086>
11. **A primer for pediatric radiologists on infection control in an era of COVID-19.** *Pediatr Radiol* 2020; Miranda-Schaeubinger M, Blumfield E, Chavhan GB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638055>
12. **Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndrome.** *Perfusion* 2020:267659120939757 Lewis D, Fisler G, Schneider J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643551>
13. **Increasing handwashing in young children: A brief review.** *J. Appl. Behav. Anal.* 2020; Jess RL, Dozier CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639051>
14. **COVID-19 in Children: An Ample Review.** *Risk Manag. Healthc. Policy* 2020; 13:661-669 Ciuca IM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636686>
15. **Pills to think about in allergic rhinitis children during COVID-19 era.** *Acta Paediatr* 2020; Brindisi G, De Vittori V, De Castro G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627237>
16. **Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the AIEOP.** *J Pediatric Infect Dis Soc* 2020; Bisogno G, Provenzi M, Zama D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652521>
17. **At home dose escalation of Propranolol for Infantile Hemangiomas during the COVID-19 Pandemic.** *Dermatol Ther* 2020:e13977 Bassi A, Azzarelli A, Vaccaro A, Mazzatenta C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633450>
18. **[Changes from COVID-19. A perspective from internal pediatric medicine].** *An Pediatr (Barc)* 2020; Alcala Minagorre PJ, Villalobos Pinto E, Ramos Fernandez JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646797>
19. **Operationalizing an Academic Pediatric Practice during the COVID-19 Crisis.** *Am. J. Infect. Control* 2020; Abuali M, Bonner R, Irigoyen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652255>

Clinical Features (28 articles)

1. **COVID-19 Epidemic: Clinical Characteristics of Patients in Pediatric Isolation Ward.** *Clin. Pediatr. (Phila.)* 2020:9922820941228 Zhu J, Wu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646234>
2. **Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis.** *Eur J Clin Microbiol Infect Dis* 2020; Zhao K, Li R, Wu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651736>
3. **Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China.** *Infect Dis Poverty* 2020; 9:85 Zhang SY, Lian JS, Hu JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641121>

4. **Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study.** *J Thorac Dis* 2020; 12:1811-1823 Wu F, Zhou Y, Wang Z *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642086>
5. **Time-dependent changes in the clinical characteristics and prognosis of hospitalized COVID-19 patients in Wuhan, China: A retrospective study.** *Clin Chim Acta* 2020; Wang M, Zhang J, Ye D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645392>
6. **Atypical Presentation of COVID-19 in an Older Adult: Lethargy and Vomiting from Severe Hypovolemic Hyponatremia.** *Geriatr Gerontol Int* 2020; Tee LY, Yap B, Sidhu GK *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639064>
7. **Comparison of clinical and microbiological diagnoses for older adults with COVID-19 in Wuhan: a retrospective study.** *Aging Clin. Exp. Res.* 2020; Sun H, Ning R, Tao Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638344>
8. **An unusual case of coronavirus disease 2019: Delayed chest CT evidence.** *J Infect Public Health* 2020; Shi X, Ma Q, Lu Y, Shi Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636075>
9. **COVID-19 related anagen effluvium.** *J Dermatolog Treat* 2020:1-4 Shanshal M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628051>
10. **A probable atypical skin manifestation of COVID-19 infection.** *J Dermatolog Treat* 2020:1-11 Shahidi Dadras M, Zargari O, Abolghasemi R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628082>
11. **Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.** *Dermatol Ther* 2020; Seirafianpour F, Sodagar S, Mohammad AP *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639077>
12. **Can SARS-CoV-2 infect the eye?-An overview of the receptor status in ocular tissue.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Schnichels S, Rohrbach JM, Bayyoud T *et al*.
13. **The First Reactive Arthritis Case Associated with COVID-19.** *J Med Virol* 2020; Saricaoglu EM, Hasanoglu I, Guner R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652541>
14. **Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients.** *Am. J. Otolaryngol.* 2020; 41:102622 Sakalli E, Temirbekov D, Bayri E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629147>
15. **[SARS-CoV-2, COVID-19 and the eye: An update on published data].** *J. Fr. Ophtalmol.* 2020; Rousseau A, Fenolland JR, Labetoulle M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631687>
16. **Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.** *Diagn. Microbiol. Infect. Dis.* 2020; 98:115094 Ortiz-Prado E, Simbana-Rivera K, Gomez-Barreno L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623267>
17. **Hematological manifestations of COVID-19.** *Leuk. Lymphoma* 2020:1-9 Mina A, Besien KV, Platanius LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643489>
18. **Observations about Symptomatic and Asymptomatic infections of 494 patients with COVID-19 in Shanghai, China.** *Am. J. Infect. Control* 2020; Mei X, Zhang Y, Zhu H *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645475>
19. **Endocrine and metabolic aspects of the COVID-19 pandemic.** *Rev. Endocr. Metab. Disord.* 2020; Marazuela M, Giustina A, Puig-Domingo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643004>
20. **Asymptomatic COVID-19 transmission: the importance of avoiding official miscommunication.** *Diagnosis (Berl)* 2020; Lippi G, Plebani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651980>
21. **What is the importance of the conjunctiva as a potential transmission pathway for SARS-CoV-2 infections?** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Lange C, Wolf J, Auw-Haedrich C *et al*.
22. **Assessment of SARS-CoV-2 in human semen-a cohort study.** *Fertil. Steril.* 2020; Holtmann N, Edimiris P, Andree M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650948>
23. **Relapsing viral keratoconjunctivitis in COVID-19: a case report.** *Virology* 2020; 17:97 Guo D, Xia J, Wang Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641169>
24. **The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries.** *J Am Acad Dermatol* 2020; Freeman EE, McMahon DE, Lipoff JB *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622888>
25. **COVID-19 associated parotitis: A case report.** *Am J Emerg Med* 2020; Fisher J, Monette DL, Patel KR *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631770>
26. **Indirect skin sign of COVID-19 days: striae rubrae.** *J Cosmet Dermatol* 2020; Ertugrul G, Aktas H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652876>
27. **Asymptomatic COVID-19 or are we missing something?** *Commun Dis Intell (2018)* 2020; 44 Daniells JK, MacCallum HL, Durrheim DN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640950>
28. **First results of investigations of SARS-CoV-2 RNA in human corneal tissue.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Bayyoud T, Iftner T, Bartz-Schmidt KU *et al*.

CNS (23 articles)

1. **Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus.** *Cell. Mol. Neurobiol.* 2020; Xu J, Lazartigues E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623546>
2. **Dementia Care in the Time of COVID-19 Pandemic.** *J. Alzheimers Dis.* 2020; Tousi B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651326>
3. **The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.** *Mult Scler Relat Disord* 2020; 45:102347 Tomczak A, Han MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645636>
4. **Analysis of ACE2 Genetic Variability among Populations Highlights a Possible Link with COVID-19-Related Neurological Complications.** *Genes (Basel)* 2020; 11 Strafella C, Caputo V, Termine A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635188>
5. **Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter CORANOSMIA cohort study.** *J Infect* 2020; Salmon D, Bartier S, Hautefort C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650110>

6. **Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients.** Am. J. Otolaryngol. 2020; 41:102622Sakalli E, Temirbekov D, Bayri E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629147>
7. **The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings.** Brain 2020; Paterson RW, Brown RL, Benjamin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637987>
8. **Potential neurological effects of severe COVID-19 infection.** Neurosci. Res. 2020; Nuzzo D, Picone P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628969>
9. **Paranasal sinuses computed tomography findings in anosmia of COVID-19.** Am. J. Otolaryngol. 2020; 41:102636Naeini AS, Karimi-Galougahi M, Raad N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652405>
10. **Bilateral paresthesia associated with cardiovascular disease and COVID-19.** Oral Dis 2020; Moreira MS, Neves ILI, de Bernoche C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640483>
11. **Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.** J. Neurol. 2020; Mateen FJ, Rezaei S, Alakel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638107>
12. **Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.** J Neurol Sci 2020; 416:117011Luca B, Tommaso G, Bavaro DF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650143>
13. **Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences.** Diabetes Metab Syndr 2020; 14:1053-1060Lahiri D, Mondal R, Deb S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640417>
14. **Guillain-Barre Syndrome Associated with SARS-CoV-2 Detection and a COVID-19 Infection in a Child.** J Pediatric Infect Dis Soc 2020; Khalifa M, Zakaria F, Ragab Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652520>
15. **Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.** Neurol Sci 2020; Hwang JM, Kim JH, Park JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643133>
16. **Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience.** Front. Neurol. 2020; 11:659Huang J, Zheng M, Tang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32625165>
17. **Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description.** Brain 2020; Hernandez-Fernandez F, Valencia HS, Barbella-Aponte RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645151>
18. **Encephalomyelitis associated with Covid-19 infection: case report.** Br. J. Neurosurg. 2020:1-3Demirci Otluglu G, Yener U, Demir MK, Yilmaz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633581>
19. **Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy.** Mult Scler Relat Disord 2020; 44:102372Crescenzo F, Marastoni D, Bovo C, Calabrese M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650121>
20. **Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!** Int. J. Immunopathol. Pharmacol. 2020; 34:2058738420941754Ciorba A, Corazzi V, Skarzynski PH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649262>
21. **Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.** J. Alzheimers Dis. 2020; Capozzo R, Zoccolella S, Frisullo ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651328>
22. **COVID-19 neuropsychological factors and considerations within the acute physical medicine and rehabilitation setting.** Brain Inj. 2020:1-2Arenivas A PhD MPH, Carter KRP, Harik LMP, Hays KMP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633633>
23. **Is Guillain-Barre syndrome triggered by SARS-CoV-2? Case report and literature review.** Neurol Sci 2020; Agosti E, Giorgianni A, D'Amore F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643136>

Complications (69 articles)

1. **Extra-pulmonary complications of COVID-19: a multi-system disease?** J Med Virol 2020; Zheng KI, Feng G, Liu WY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648973>
2. **Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU.** Clin Chim Acta 2020; Zhang D, Zhou X, Yan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645391>
3. **Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae.** J Infect 2020; Zha L, Shen J, Tefsen B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652163>
4. **Association of Padua prediction score with in-hospital prognosis in COVID-19 patients.** QJM 2020; Zeng DX, Xu JL, Mao QX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652021>
5. **Successful coronary artery bypass operation in a SARS-COV-2 infected patient with acute coronary syndrome.** J. Card. Surg. 2020; Yandrapalli S, Cooper HA, Malekan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652660>
6. **Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China.** Crit Care 2020; 24:394Xu J, Yang X, Yang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631393>
7. **Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus.** Cell. Mol. Neurobiol. 2020; Xu J, Lazartigues E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623546>
8. **Aligning difficult airway guidelines with the anesthetic COVID-19 guidelines to develop a COVID-19 difficult airway strategy: a narrative review.** J. Anesth. 2020; Wong P, Lim WY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642840>
9. **Bloodstream Infection by Saccharomyces cerevisiae in Two COVID-19 Patients after Receiving Supplementation of Saccharomyces in the ICU.** J Fungi (Basel) 2020; 6Ventoulis I, Sarmourli T, Amoiridou P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630111>
10. **Possible formation of pulmonary microthrombi in the early puerperium of pregnant women critically ill with COVID-19: Two case reports.** Case Rep Womens Health 2020; 27:e00237Tutiya CT, Sialyls MM, Kondo MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637327>

11. **Pneumococcal co-infection in Covid-19 patients.** *J Med Virol* 2020; Toombs J, Van den Abbeele K, Democratis J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639585>
12. **Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues.** *Fertil. Steril.* 2020; 114:33-43 Stanley KE, Thomas E, Leaver M, Wells D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622411>
13. **Tocilizumab for treatment of mechanically ventilated patients with COVID-19.** *Clin Infect Dis* 2020; Somers EC, Eschenauer GA, Troost JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651997>
14. **Practical considerations in prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19.** *Am. J. Health Syst. Pharm.* 2020; Smith K, Krajewski KC, Krajewski MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628248>
15. **COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.** *Clin. Neurol. Neurosurg.* 2020; 196:106045 Singh S, Govindarajan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634699>
16. **Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic.** *Clin Res Cardiol* 2020; Scheller B, Vukadinovic D, Ewen S, Mahfoud F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623491>
17. **Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.** *Transpl Infect Dis* 2020:e13401 Saraceni F, Scortechini I, Mancini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629531>
18. **Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis.** *J Thromb Haemost* 2020; Santoliquido A, Porfida A, Nesci A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633068>
19. **Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain.** *E Clinical Medicine* 2020; 23:100407 San-Juan R, Barbero P, Fernandez-Ruiz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632417>
20. **Cold agglutinin disease and autoimmune hemolytic anemia with pulmonary embolism as a presentation of COVID-19 infection.** *Hematol. Oncol. Stem Cell Ther.* 2020; Patil NR, Herc ES, Girgis M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645300>
21. **Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020.** *Emerg Infect Dis* 2020; 26 Panepinto JA, Brandow A, Mucalo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639228>
22. **Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2.** *Respir. Physiol. Neurobiol.* 2020:103489 Pagano A, Porta G, Bosso G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629100>
23. **Potential neurological effects of severe COVID-19 infection.** *Neurosci. Res.* 2020; Nuzzo D, Picone P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628969>
24. **Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events.** *Diabetes Metab Syndr* 2020; 14:1017-1025 Nandy K, Salunke A, Pathak SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634716>
25. **Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management.** *Children (Basel)* 2020; 7 Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630212>
26. **Rhabdomyolysis in a Patient With Coronavirus Disease 2019.** *Cureus* 2020; 12:e8956 Mukherjee A, Ghosh R, Aftab G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642390>
27. **Percutaneous dilatational tracheostomy for saturating influx of COVID-19 patients: Experience of military ENT physicians deployed in Mulhouse, France.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Morvan JB, Riviere D, Danguy des Deserts M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631724>
28. **Bilateral paresthesia associated with cardiovascular disease and COVID-19.** *Oral Dis* 2020; Moreira MS, Neves ILI, de Bernoche C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640483>
29. **COVID-19 and HIV co-infection an emerging consensus.** *J Med Virol* 2020; Masukume G, Mapanga W, Grinberg S, van Zyl DS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633849>
30. **SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine.** *Radiat Oncol* 2020; 15:165 Marschner S, Corradini S, Rauch J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646505>
31. **COVID-ARDS Clarified: A Vascular Endotype?** *Am J Respir Crit Care Med* 2020; Mangalmurti NS, Reilly JP, Cines DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631071>
32. **Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state.** *J Matern Fetal Neonatal Med* 2020:1-9 Makatsariya AD, Slukhanchuk EV, Bitsadze VO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627622>
33. **Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China.** *Aging (Albany NY)* 2020; 12 Liu X, Zheng X, Liu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628642>
34. **Prevalence and predictive value of hypocalcemia in severe COVID-19 patients.** *J Infect Public Health* 2020; Liu J, Han P, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622796>
35. **Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndrome.** *Perfusion* 2020:267659120939757 Lewis D, Fislser G, Schneider J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643551>
36. **Myopericarditis, Rhabdomyolysis, and Acute Hepatic Injury: Sole Expression of a SARS-CoV-2 Infection.** *Circ. Cardiovasc. Imaging* 2020; 13:e010907 Legrand F, Chong-Nguyen C, Ghanem N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635747>
37. **Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19.** *Crit Care* 2020; 24:412 Laverdure F, Delaporte A, Bouteau A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646470>
38. **Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.** *Cells* 2020; 9 Labo N, Ohnuki H, Tosato G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629875>
39. **Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study.** *Clin Infect Dis* 2020; Kragholm K, Andersen MP, Gerds TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634827>

40. **Severe refractory thrombocytopenia in a woman positive for coronavirus disease 2019 with lupus and antiphospholipid syndrome.** Lupus 2020;961203320940389Hayden A, Vyas-Lahar A, Rella V, Rudinskaya A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640936>
41. **COVID-19 and Salmonella Typhi co-epidemics in Pakistan: A real problem.** J Med Virol 2020; Haqqi A, Khurram M, Din MSU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648942>
42. **Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.** J Med Virol 2020; Gomez-Mayordomo V, Montero-Escribano P, Matias-Guiu JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644205>
43. **Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis.** Eur Radiol 2020; Francone M, Iafrate F, Masci GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623505>
44. **Unusual Microbleeds in Brain MRI of Covid-19 Patients.** J. Neuroimaging 2020; Fitsiori A, Pugin D, Thieffry C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639679>
45. **Percutaneous tracheostomy simulation training for ENT physicians in the treatment of COVID-19-positive patients.** Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2020; Favier V, Kimmoun A, Gatin A, Gallet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624392>
46. **Spontaneous Pneumomediastinum/Pneumothorax in Patients With COVID-19.** Cureus 2020; 12:e8996Eperjesiova B, Hart E, Shokr M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642391>
47. **Drape to Prevent Disease Transmission During Endotracheal Intubation.** Am. J. Infect. Control 2020; Emami N, Taner T, Ogundipe F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628982>
48. **Concerns for low-resource countries, with under-prepared intensive care units, facing the COVID-19 pandemic.** Infect Dis Health 2020; Elhadi M, Msherghi A, Alkeelani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631682>
49. **SARS-CoV-2 and Male Infertility: Possible Multifaceted Pathology.** Reprod. Sci. 2020; Dutta S, Sengupta P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651900>
50. **Pathophysiology of SARS-CoV-2 infection in patients with intracerebral hemorrhage.** Aging (Albany NY) 2020; 12Dong S, Liu P, Luo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633728>
51. **A Challenging Colectomy for Acute Severe Ulcerative Colitis Complicated by COVID-19.** Inflamm. Bowel Dis. 2020; Di Ruscio M, Variola A, Angheben A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626898>
52. **Aortic thrombus in patients with severe COVID-19: review of three cases.** J. Thromb. Thrombolysis 2020; de Carranza M, Salazar DE, Troya J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648092>
53. **NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection.** Therapie 2020; Cumhur Cure M, Kucuk A, Cure E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636031>
54. **Cardiac arrest precipitated by succinylcholine in a patient with COVID-19. Comment on Br J Anaesth 2020; 10.1016/j.bja.2020.04.073.** Br J Anaesth 2020; Crockett DC, Frise MC, Strachan JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624186>
55. **Physician drug prescribing preferences and availability for ventilation of patients with COVID-19.** Crit Care Resusc 2020; Coombes ID, Dooley MJ, Townsend S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640769>
56. **Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.** Cell. Signal. 2020;109706Chen X, Geiger JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629149>
57. **Pregnancy with Covid-19: Management considerations for care of severe and critically ill cases.** Am. J. Reprod. Immunol. 2020:e13299Chen L, Jiang H, Zhao Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623810>
58. **Distinct clinical characteristics and risk factors for mortality in female COVID-19 inpatients: a sex-stratified large-scale cohort study in Wuhan, China.** Clin Infect Dis 2020; Chen J, Bai H, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634830>
59. **Underestimation of co-infections in COVID-19 due to non-discriminatory use of antibiotics.** J Infect 2020; Chang CY, Chan KG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628960>
60. **First, do no harm: bilateral radial artery occlusion in a COVID-19 patient.** J. Clin. Monit. Comput. 2020; Bouwhuis A, Schober P, Heunks LMA, Schwarte LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632667>
61. **Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the AIEOP.** J Pediatric Infect Dis Soc 2020; Bisogno G, Provenzi M, Zama D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652521>
62. **ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS.** Am. J. Pathol. 2020; Argyropoulos KV, Serrano A, Hu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628931>
63. **A Saudi family with sickle cell disease presented with acute crises and COVID-19 infection.** Pediatr Blood Cancer 2020:e28547Al-Hebshi A, Zolaly M, Alshengeti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648991>
64. **Rare Presentation of Pulmonary Embolism Amidst Coronavirus Disease 2019 Era: Utility of Multiorgan Ultrasonography.** Cureus 2020; 12:e8452Ahmed T, Ahmed T, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642364>
65. **COVID-19 and fungal co-infections: We must keep them in mind.** J. Mycol. Med. 2020:101012Agrifoglio A, Cachafeiro L, Figueira JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651137>
66. **A severe refractory COVID-19 patient responding to convalescent plasma; A case series.** Ann Med Surg (Lond) 2020; 56:125-127Abdullah HM, Hama-Ali HH, Ahmed SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637086>

Cured – Recovered (2 articles)

1. **COVID-19: Outcomes of patients with confirmed COVID-19 re-admitted to hospital.** J Infect 2020; Rokadiya S, Gil E, Stubbs C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652166>
2. **Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases.** J Am Geriatr Soc 2020; Lafaie L, Celarier T, Goethals L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638347>

Cardiovascular disease (56 articles)

1. **Multimodality Cardiovascular Imaging in the Midst of the COVID-19 Pandemic: Ramping Up Safely to a New Normal.** *JACC Cardiovasc. Imaging* 2020; 13:1615-1626 Zoghbi WA, DiCarli MF, Blankstein R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646721>
2. **Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Zhang Y, Cao W, Jiang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648093>
3. **Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU.** *Clin Chim Acta* 2020; Zhang D, Zhou X, Yan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645391>
4. **Successful coronary artery bypass operation in a SARS-COV-2 infected patient with acute coronary syndrome.** *J. Card. Surg.* 2020; Yandrapalli S, Cooper HA, Malekan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652660>
5. **Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm.** *J Clin Med* 2020; 9Vinciguerra M, Romiti S, Fattouch K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635302>
6. **Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19.** *Neth. Heart J.* 2020; van den Heuvel FMA, Vos JL, Koop Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643071>
7. **Two patients with COVID-19 and a fever-induced Brugada-like electrocardiographic pattern.** *Neth. Heart J.* 2020; van de Poll SWE, van der Werf C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643073>
8. **Possible formation of pulmonary microthrombi in the early puerperium of pregnant women critically ill with COVID-19: Two case reports.** *Case Rep Womens Health* 2020; 27:e00237 Tutiya CT, Sialyls MM, Kondo MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637327>
9. **COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult.** *Am J Emerg Med* 2020; Sokolovsky S, Soni P, Hoffman T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631771>
10. **Practical considerations in prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19.** *Am. J. Health Syst. Pharm.* 2020; Smith K, Krajewski KC, Krajewski MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628248>
11. **The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.** *Neth. Heart J.* 2020; Sinkeler FS, Berger FA, Muntinga HJ, Jansen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648153>
12. **Cardiac manifestations in COVID-19 patients-A systematic review.** *J. Card. Surg.* 2020; Shafi AMA, Shaikh SA, Shirke MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652713>
13. **Caring for adults with congenital heart disease in the era of Covid-19 pandemic: Early experience in an Italian tertiary centre.** *Cardiol. Young* 2020;1-13 Scognamiglio G, Fusco F, Merola A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624052>
14. **DISEQUILIBRIUM BETWEEN THE CLASSIC RENIN-ANGIOTENSIN SYSTEM AND ITS OPPOSING ARM IN SARS-COV-2 RELATED LUNG INJURY.** *Am J Physiol Lung Cell Mol Physiol* 2020; Sarzani R, Giulietti F, Di Pentima C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639866>
15. **Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis.** *J Thromb Haemost* 2020; Santoliquido A, Porfidia A, Nesci A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633068>
16. **Cardiac biomarkers and COVID-19 - Phenotypes and Interpretation.** *Deutsche Medizinische Wochenschrift* 2020; 145:755-760 Salbach C, Giannitsis E.
17. **COVID-19 and Stroke: Casual or Causal Role?** *Cerebrovasc. Dis.* 2020;1-4 Saggese CE, Del Bianco C, Di Ruzza MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634813>
18. **Cerebrovascular Disease in Patients with COVID-19: A Review of the Literature and Case Series.** *Case Rep. Neurol.* 2020; 12:199-209 Reddy ST, Garg T, Shah C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647526>
19. **Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature.** *Adv Ther* 2020; Rahimi L, Malek M, Ismail-Beigi F, Khamseh ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632851>
20. **Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?** *JAMA Netw Open* 2020; 3:e2013556 Rabbani AB, Parikh RV, Rafique AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579190>
21. **Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.** *Clin Infect Dis* 2020; Oussalah A, Gleye S, Clerc Urmes I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623470>
22. **Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.** *Heart Rhythm* 2020; Offerhaus JA, Wilde AAM, Remme CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622993>
23. **Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients.** *Med. Intensiva* 2020; Moreno G, Carbonell R, Bodi M, Rodriguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646669>
24. **Bilateral paresthesia associated with cardiovascular disease and COVID-19.** *Oral Dis* 2020; Moreira MS, Neves ILI, de Bernoche C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640483>
25. **Acute stroke care during the COVID-19 pandemic: difficult, but not impossible!** *Acta Neurol. Belg.* 2020; Maldonado Sloopjes S, Hammer F, Leempoel J, Peeters A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638268>
26. **Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state.** *J Matern Fetal Neonatal Med* 2020;1-9 Makatsariya AD, Slukhanchuk EV, Bitsadze VO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627622>
27. **Large vessel stroke and COVID-19: Case report and literature review.** *eNeurologicalSci* 2020; 20:100250 Mahboob S, Boppana SH, Rose NB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632380>
28. **Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2.** *J Cell Mol Med* 2020; Li Y, Xu Q, Ma L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639084>

29. **Myopericarditis, Rhabdomyolysis, and Acute Hepatic Injury: Sole Expression of a SARS-CoV-2 Infection.** *Circ. Cardiovasc. Imaging* 2020; 13:e010907 Legrand F, Chong-Nguyen C, Ghanem N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635747>
30. **Endocrine significance of SARS-CoV-2's reliance on ACE2.** *Endocrinology* 2020; Lazartigues E, Qadir MMF, Mauvais-Jarvis F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652001>
31. **Worrying decrease in hospital admissions for myocardial infarction during the COVID-19 pandemic.** *Arch Cardiovasc Dis* 2020; Lantelme P, Couray Targe S, Metral P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636131>
32. **Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.** *Cells* 2020; 9Labo N, Ohnuki H, Tosato G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629875>
33. **Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury.** *J Am Soc Nephrol* 2020; Kow CS, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639940>
34. **COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.** *J. Clin. Hypertens. (Greenwich)* 2020; Kario K, Morisawa Y, Sukonthasarn A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643874>
35. **Impact of a nationwide COVID-19 lockdown on acute coronary syndrome referrals.** *Cardiol J* 2020; Holy EW, Jakob P, Manka R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643140>
36. **Examining the impact of COVID-19 on cardiac surgery services: The lessons learned from this pandemic.** *J. Card. Surg.* 2020; Harky A, Chen R, Pullan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643830>
37. **Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS.** *Cureus* 2020; 12:e8411 Gumashta J, Gumashta R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626626>
38. **Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors.** *Med Clin (Barc)* 2020; Golpe R, Perez-de-Llano LA, Dacal D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651067>
39. **The rapid transformation of cardiac surgery practice in the coronavirus disease 2019 (COVID-19) pandemic: Insights and clinical strategies from a center at the epicenter.** *J. Thorac. Cardiovasc. Surg.* 2020; George I, Salna M, Kobsa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624303>
40. **Telephone based survey in adults with congenital heart disease during COVID-19 pandemic.** *Cardiol J* 2020; Frogoudaki AA, Farmakis D, Tsounis D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643139>
41. **Unusual Microbleeds in Brain MRI of Covid-19 Patients.** *J. Neuroimaging* 2020; Fitsiori A, Pugin D, Thieffry C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639679>
42. **Heart Transplantation in the Era of the SARS-CoV-2 Pandemic: Is It Safe and Feasible?** *Clin. Transplant.* 2020:e14029 Esmailian G, Kobashigawa JA, Nishihara K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633819>
43. **Pathophysiology of SARS-CoV-2 infection in patients with intracerebral hemorrhage.** *Aging (Albany, NY)* 2020; 12Dong S, Liu P, Luo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633728>
44. **Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.** *JAMA Netw Open* 2020; 3:e2013136 DeFtereos SG, Giannopoulos G, Vrachatis DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579195>
45. **Aortic thrombus in patients with severe COVID-19: review of three cases.** *J. Thromb. Thrombolysis* 2020; de Carranza M, Salazar DE, Troya J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648092>
46. **Cardiovascular and immunological implications of social distancing in the context of COVID-19.** *Cardiovasc Res* 2020; D'Acquisto F, Hamilton A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638025>
47. **NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection.** *Therapie* 2020; Cumhur Cure M, Kucuk A, Cure E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636031>
48. **Cardiac arrest precipitated by succinylcholine in a patient with COVID-19. Comment on Br J Anaesth 2020; 10.1016/j.bja.2020.04.073.** *Br J Anaesth* 2020; Crockett DC, Frise MC, Strachan JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624186>
49. **Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.** *Cell. Signal.* 2020:109706 Chen X, Geiger JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629149>
50. **Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.** *Ir. J. Med. Sci.* 2020; Carron J, Sharif Z, Hussein H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627127>
51. **First, do no harm: bilateral radial artery occlusion in a COVID-19 patient.** *J. Clin. Monit. Comput.* 2020; Bouwhuis A, Schober P, Heunks LMA, Schwarte LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632667>
52. **A Review of Acute Myocardial Injury in Coronavirus Disease 2019.** *Cureus* 2020; 12:e8426B KA, Chaudhuri D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642342>
53. **Does the novel coronavirus 2019 like heart more than the other family members of coronaviruses?** *J Cardiovasc Thorac Res* 2020; 12:156-157 Ansari Ramandi MM, Baay M, Naderi N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626559>
54. **Angiotensin II Receptors - Impact for COVID-19 Severity.** *Dermatol Ther* 2020:e13989 Aksoy H, Karadag AS, Wollina U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645228>
55. **Rare Presentation of Pulmonary Embolism Amidst Coronavirus Disease 2019 Era: Utility of Multiorgan Ultrasonography.** *Cureus* 2020; 12:e8452 Ahmed T, Ahmed T, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642364>
56. **COVID-19 pandemic and its impact on service provision: A cardiology prospect.** *Acta Cardiol.* 2020:1-8 Adam S, Zahra SA, Chor CYT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646309>

Diagnosis (2 articles)

1. **Comparison of clinical and microbiological diagnoses for older adults with COVID-19 in Wuhan: a retrospective study.** *Aging Clin. Exp. Res.* 2020; Sun H, Ning R, Tao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638344>

2. **The COVID-19 Diagnostic Technology Landscape: Efficient Data Sharing Drives Diagnostic Development.** *Front Public Health* 2020; 8:309Aguiar E, Navas J, Pacheco LGC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626682>

DM-MS-Obesity (18 articles)

1. **Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes.** *J. Diabetes Complications* 2020:107666Zhang Q, Wei Y, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636061>
2. **The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19.** *J. Diabetes* 2020; Xu Z, Wang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638507>
3. **Obesity and Higher Risk for Severe Complications of Covid-19: What to do when the two pandemics meet.** *J. Popul. Ther. Clin. Pharmacol.* 2020; 27:e31-e36Valerio A, Nisoli E, Rossi AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650354>
4. **COVID-19 Impact on People with Diabetes in the South and Central America.** *Diabetes Res Clin Pract* 2020:108301Thomaz Ugliara Barone M, Villarroel D, Vieira de Luca P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623036>
5. **The Impact of COVID-19 on People with Diabetes in Brazil.** *Diabetes Res Clin Pract* 2020:108304Thomaz Ugliara Barone M, Bega Harnik S, Vieira de Luca P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623040>
6. **COVID-19 and diabetes: What have we learned so far?** *Clin Med (Lond)* 2020; Taher N, Huda MS, Chowdhury TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628128>
7. **Vitamin D deficiency in patients with diabetes and COVID-19 infection.** *Diabetes Metab Syndr* 2020; 14:1033-1035Singh SK, Jain R, Singh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640414>
8. **Hyperglycaemia on admission to hospital and COVID-19.** *Diabetologia* 2020; Sardu C, D'Onofrio N, Balestrieri ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632527>
9. **Changes in Weight and Nutritional Habits in Adults with Obesity during the "Lockdown" Period Caused by the COVID-19 Virus Emergency.** *Nutrients* 2020; 12Pellegrini M, Ponzio V, Rosato R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645970>
10. **Association of diabetes and hypertension with disease severity in covid-19 patients: a systematic literature review and exploratory meta-analysis.** *Diabetes Res Clin Pract* 2020:108295Parveen R, Sehar N, Bajpai R, Bharal Agarwal N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623032>
11. **Obesity and COVID-19: Oro-Naso-Sensory Perception.** *J Clin Med* 2020; 9Khan AS, Hichami A, Khan NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650509>
12. **Diabetes and COVID-19: Global and Regional Perspectives.** *Diabetes Res Clin Pract* 2020:108303Jeong IK, Ho Yoon K, Kyu Lee M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623038>
13. **SGLT2 inhibition and COVID-19: The road not taken.** *Eur. J. Clin. Invest.* 2020:e13339Das L, Dutta P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648935>
14. **Letter to the Editor in response to the article "Lack of type 1 diabetes involvement in the SARS-CoV-2 population: Only a particular coincidence?"** *Diabetes Res Clin Pract* 2020:108306Charles Bronson S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623033>
15. **COVID-19 in people living with diabetes: An international consensus.** *J. Diabetes Complications* 2020:107671Caballero AE, Ceriello A, Misra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651031>
16. **Practical Recommendations for diabetes management in patients with COVID-19 disease.** *Diabetologie und Stoffwechsel* 2020; 15:241-246Bornstein SR, Gallwitz B, Kellerer M *et al.*
17. **Coronavirus disease (Covid-19): how does the exercise practice in active people with Type 1 Diabetes change? A preliminary survey.** *Diabetes Res Clin Pract* 2020:108297Assaloni R, Carnevale Pellino V, Puci MV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623042>
18. **Risk Factors for Mortality among COVID-19 Patients.** *Diabetes Res Clin Pract* 2020:108293Albitar O, Ballouze R, Ping Ooi J, Maisharah Sheikh Ghadzi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623035>

Education and training and science (28 articles)

1. **The evaluation of online course of Traditional Chinese Medicine for MBBS international students during the COVID-19 epidemic period.** *Integr Med Res* 2020; 9:100449Zhang Q, He YJ, Zhu YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632357>
2. **Research on COVID-19 based on ARIMA model(Delta)-Taking Hubei, China as an example to see the epidemic in Italy.** *J Infect Public Health* 2020; Yang Q, Wang J, Ma H, Wang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624404>
3. **Full Throttle: COVID-19 Open Science to Build Planetary Public Goods.** *OMICS* 2020; Von Schomberg R, Ozdemir V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628565>
4. **A case-based learning approach to online biochemistry labs during COVID-19.** *Biochem Mol Biol Educ* 2020; Thibaut D, Schroeder KT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652794>
5. **Impact of the Covid-19 pandemic on perceptions and behaviors of university students in Vietnam.** *Data Brief* 2020; 31:105880Nguyen DV, Pham GH, Nguyen DN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637490>
6. **COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspective.** *Cancer Med* 2020; Marcum M, Kurtzweil N, Vollmer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648667>
7. **A review of big data and medical research.** *SAGE Open Med* 2020; 8:2050312120934839Mallappallil M, Sabu J, Gruessner A, Salifu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637104>
8. **Assessment of YouTube as an Educational Tool in Teaching Key Indicator Cases in Otolaryngology During the COVID-19 Pandemic and Beyond: Neck Dissection.** *J Surg Educ* 2020; Luu NN, Yver CM, Douglas JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646815>
9. **Impact of COVID-19 epidemic on live online dental continuing education.** *Eur. J. Dent. Educ.* 2020; Liu X, Zhou J, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648989>

10. **Building Telemedicine Capacity for Trainees During the Novel Coronavirus Outbreak: a Case Study and Lessons Learned.** *J Gen Intern Med* 2020; Lawrence K, Hanley K, Adams J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642929>
11. **Maintaining High-Quality Multidisciplinary Pain Medicine Fellowship Programs: Part I: Innovations in Pain Fellows' Education, Research, Applicant Selection Process, Wellness, and ACGME Implementation During the COVID-19 Pandemic.** *Pain Med* 2020; Kohan L, Moeschler S, Spektor B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632454>
12. **Applying to dermatology residency during the COVID-19 pandemic.** *J Am Acad Dermatol* 2020; Kearns DG, Chat VS, Uppal S, Wu JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652192>
13. **The most cited and co-cited COVID-19 articles: Knowledge base for rehabilitation team members.** *Work* 2020; Irmak R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623414>
14. **Conducting Inpatient Dermatology Consultations and Maintaining Resident Education in the COVID-19 Telemedicine Era.** *J Am Acad Dermatol* 2020; Hammond MI, Sharma TR, Cooper KD, Beveridge MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652186>
15. **Effect of COVID-19 in selecting otolaryngology as a specialty.** *Head Neck* 2020; 42:1409-1410Go B, Rajasekaran K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633093>
16. **School's Out for COVID-19: 50 Ways BCBA Trainees in Special Education Settings Can Accrue Independent Fieldwork Experience Hours During the Pandemic.** *Behav Anal Pract* 2020; 13:312-320Fronapfel BH, Demchak M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637294>
17. **Use of whole slide imaging (WSI) for distance teaching.** *J. Clin. Pathol.* 2020; Evans AJ, Depeiza N, Allen SG *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646928>
18. **Clinical trials in the time of a pandemic.** *Clin. Trials* 2020:1740774520939871Ellenberg SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650672>
19. **The transition from objectively structured practical examination (OSPE) to electronic OSPE in the era of COVID-19.** *Biochem Mol Biol Educ* 2020; Dutta AK, Goswami K, Murugaiyan S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652639>
20. **Cardiopulmonary Considerations for High School Student-Athletes During the COVID-19 Pandemic: NFHS-AMSSM Guidance Statement.** *Sports Health* 2020:1941738120941490Drezner JA, Heinz WM, Asif IM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640879>
21. **Conducting research in Radiation Oncology remotely during the COVID-19 pandemic: Coping with isolation.** *Clin Transl Radiat Oncol* 2020; 24:53-59Dhont J, Di Tella M, Dubois L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632379>
22. **SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.** *Theranostics* 2020; 10:7448-7464Datta PK, Liu F, Fischer T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642005>
23. **The COVID-19 AAGP Online Trainee Curriculum: Development and Method of Initial Evaluation.** *Am J Geriatr Psychiatry* 2020; Conroy ML, Garcia-Pittman EC, Ali H *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624338>
24. **The impact of COVID-19 pandemic on orthopaedic resident education: a nationwide survey study in South Korea.** *Int. Orthop.* 2020; Chang DG, Park JB, Baek GH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651712>
25. **The Importance of Publishing Non-COVID-19 Research during COVID-19.** *J. Clin. Epidemiol.* 2020; Chaitoff A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622899>
26. **COVID-19 and anatomy: Stimulus and initial response.** *J. Anat.* 2020; Brassett C, Cosker T, Davies DC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628795>
27. **Sustainable Diabetes Care Services during COVID-19 Pandemic.** *Diabetes Res Clin Pract* 2020:108298Alromaihi D, Alamuddin N, George S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623031>
28. **An 'alarming' and 'exceptionally high' rate of COVID-19 retractions?** *Account Res* 2020; Abritis A, Marcus A, Oransky I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634321>

Elderly (11 articles)

1. **Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.** *Curr Drug Metab* 2020; Yao X, Hou Z, Cui C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651961>
2. **(Vi)-rushed Into Online Group Schema Therapy Based Day-Treatment for Older Adults by the COVID-19 Outbreak in the Netherlands.** *Am J Geriatr Psychiatry* 2020; van Dijk SDM, Bouman R, Folmer EH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622730>
3. **Atypical Presentation of COVID-19 in an Older Adult: Lethargy and Vomiting from Severe Hypovolemic Hyponatremia.** *Geriatr Gerontol Int* 2020; Tee LY, Yap B, Sidhu GK *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639064>
4. **Clinical observations in the very elderly patients with COVID-19 in Wuhan.** *Geriatr Gerontol Int* 2020; Rui L, Sirui L, Xuebei D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634855>
5. **Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.** *Geriatr Gerontol Int* 2020; Osawa A, Maeshima S, Kondo I, Arai H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639083>
6. **National Geriatric Network Rapidly Addresses Trainee Telehealth Needs in Response to COVID-19.** *J Am Geriatr Soc* 2020; Nearing KA, Lum HD, Dang S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639578>
7. **Frailty and COVID-19: A Systematic Scoping Review.** *J Clin Med* 2020; 9Maltese G, Corsonello A, Di Rosa M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635468>
8. **Older people and COVID-19 updates by medical postgraduate colleges in UK and Ireland.** *Eur. Geriatr. Med.* 2020; Lynch A, O'Neill D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651752>
9. **Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases.** *J Am Geriatr Soc* 2020; Lafaie L, Celarier T, Goethals L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638347>
10. **Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:635Gopel S, Bethge W, Martus P *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650818>

11. **Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan, China.** *Aging (Albany NY)* 2020; 12:Gao S, Jiang F, Jin W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651993>

Epidemiology 76 articles)

1. **Why communities must be at the centre of the Coronavirus disease 2019 response: Lessons from Ebola and human immunodeficiency virus in Africa.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3. Johnson O, Goronga T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634005>
2. **A retrospective analysis of the epidemiology, clinical manifestations, and imaging characteristics of familial cluster-onset COVID-19.** *Ann Transl Med* 2020; 8:747. Huang K, Zhang J, Wu W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647672>
3. **Understanding of Young People About COVID-19 During Early Outbreak in Indonesia.** *Asia Pac. J. Public Health* 2020:1010539520940933. Adella Halim D, Kurniawan A, Agung FH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643963>
4. **CoVid-19 Pandemic Trend Modeling and Analysis to Support Resilience Decision-Making.** *Biology (Base)* 2020; 9:Duffey RB, Zio E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646014>
5. **Social distancing, population density, and spread of COVID-19 in England: a longitudinal study.** *BJGP Open* 2020; Tammes P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636204>
6. **Coronavirus pandemic: applying a whole-of-society model for the whole-of-the world.** *Br. J. Oral Maxillofac. Surg.* 2020; Dubb SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631753>
7. **Impact of a nationwide COVID-19 lockdown on acute coronary syndrome referrals.** *Cardiol J* 2020; Holy EW, Jakob P, Manka R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643140>
8. **Cardiovascular and immunological implications of social distancing in the context of COVID-19.** *Cardiovasc Res* 2020; D'Acquisto F, Hamilton A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638025>
9. **COVID-19 and "natural" experiments arising from physical distancing: a hypothetical case study from chronobiology.** *Chronobiol. Int.* 2020:1-3. Erren TC, Lewis P, Shaw DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633583>
10. **When hospitals Harm: Multi-modal entry of SARS-CoV-2 into inpatient healthcare.** *Clin Infect Dis* 2020; Curry SR, Salgado CD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648903>
11. **Development and delivery of a real-time hospital-onset COVID-19 surveillance system using network analysis.** *Clin Infect Dis* 2020; Price JR, Mookerjee S, Dyakova E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634822>
12. **Rapid Emergence of SARS-CoV-2 in the Greater New York Metropolitan Area: Geolocation, Demographics, Positivity Rates, and Hospitalization for 46,793 Persons Tested by Northwell Health.** *Clin Infect Dis* 2020; Reichberg SB, Mitra PP, Haghmagad A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640030>
13. **Spatiotemporal Characteristics of COVID-19 Epidemic in the United States.** *Clin Infect Dis* 2020; Wang Y, Liu Y, Struthers J, Lian M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640020>
14. **The I in COVID: The importance of community and patient involvement in COVID-19 research.** *Clin Med (Lond)* 2020; Ratneswaren A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628127>
15. **Knowledge, Attitudes, and Practices Toward COVID-19 in a Saudi Arabian Population: A Cross-Sectional Study.** *Cureus* 2020; 12:e8905. Almfada SK, Alherbisch RJ, Almuhraj NA *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637289>
16. **Screening of Mothers in a COVID-19 Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers from Rostock by ELISA and Confirmation by Immunofluorescence.** *Deutsche medizinische Wochenschrift (1946)* 2020; Reisinger EC, von Possel R, Warnke P *et al*.
17. **Asymptomatic COVID-19 transmission: the importance of avoiding official miscommunication.** *Diagnosis (Berl)* 2020; Lippi G, Plebani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651980>
18. **Rapid Large-Scale COVID-19 Testing During Shortages.** *Diagnostics (Basel)* 2020; 10:Beetz C, Skrahina V, Forster TM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650631>
19. **Coronavirus Disease Exposure and Spread from Nightclubs, South Korea.** *Emerg Infect Dis* 2020; 26:Kang CR, Lee JY, Park Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633713>
20. **Social and administrative issues related to the COVID-19 pandemic in Pakistan: better late than never.** *Environ. Sci. Pollut. Res. Int.* 2020; Anser MK, Yousaf Z, Khan MA *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648218>
21. **Reply to "Could a mannequin simplify rhinopharyngeal swab collection in COVID 19 patients?".** *Eur Arch Otorhinolaryngol* 2020; Tagliabue M, Pietrobon G, Ugolini S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648031>
22. **Assessment of SARS-CoV-2 in human semen-a cohort study.** *Fertil. Steril.* 2020; Holtmann N, Edimiris P, Andree M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650948>
23. **Strongly Heterogeneous Transmission of COVID-19 in Mainland China: Local and Regional Variation.** *Front Med (Lausanne)* 2020; 7:329. Wang Y, Teunis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637423>
24. **Too Much Information: Assessing Privacy Risks of Contact Trace Data Disclosure on People With COVID-19 in South Korea.** *Front Public Health* 2020; 8:305. Jung G, Lee H, Kim A, Lee U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626681>
25. **Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis.** *Global Health* 2020; 16:57. Salari N, Hosseini-Far A, Jalali R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631403>
26. **Shelter-In-Place Orders Reduced COVID-19 Mortality And Reduced The Rate Of Growth In Hospitalizations.** *Health Aff (Millwood)* 2020:101377. Hlthaff202000719. Lyu W, Wehby GL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644825>
27. **United but divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak.** *Health Policy* 2020; Sabat I, Neuman-Bohme S, Varghese NE *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631613>
28. **How Shenzhen, China avoided widespread community transmission: a potential model for successful prevention and control of COVID-19.** *Infect Dis Poverty* 2020; 9:89. Zou H, Shu Y, Feng T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650840>

29. **Transmission patterns of COVID-19 in the mainland of China and the efficacy of different control strategies: a data- and model-driven study.** *Infect Dis Poverty* 2020; 9:83Zu J, Li ML, Li ZF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631426>
30. **A real-time policy dashboard can aid global transparency in the response to coronavirus disease 2019.** *Int Health* 2020; Head MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648909>
31. **Predicting the Epidemiological Outbreak of the Coronavirus Disease 2019 (COVID-19) in Saudi Arabia.** *Int J Environ Res Public Health* 2020; 17Alboaneen D, Pranggono B, Alshammari D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630363>
32. **Modeling and Forecasting the COVID-19 Temporal Spread in Greece: An Exploratory Approach based on Complex Network Defined Splines.** *Int J Environ Res Public Health* 2020; 17Demertzis K, Tsiotas D, Magafas L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629791>
33. **The Outcome and Implications of Public Precautionary Measures in Taiwan-Declining Respiratory Disease Cases in the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Hsieh CC, Lin CH, Wang WYC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640752>
34. **Prevalence and Predictors of Anxiety and Depression Symptoms during the COVID-19 Pandemic and Compliance with Precautionary Measures: Age and Sex Matter.** *Int J Environ Res Public Health* 2020; 17Solomou I, Constantinidou F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650522>
35. **Prediction of the Number of Patients Infected with COVID-19 Based on Rolling Grey Verhulst Models.** *Int J Environ Res Public Health* 2020; 17Zhao YF, Shou MH, Wang ZX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630565>
36. **Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank.** *Int J Equity Health* 2020; 19:114Patel AP, Paranjpe MD, Kathiresan NP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631328>
37. **Geostatistical COVID-19 infection risk maps for Portugal.** *Int J Health Geogr* 2020; 19:25Azevedo L, Pereira MJ, Ribeiro MC, Soares A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631358>
38. **The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review.** *Int J Infect Dis* 2020; Al-Sadeq DW, Nasrallah GK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623083>
39. **Covid-19 exposure risk for family members of healthcare workers: an observational study.** *Int J Infect Dis* 2020; Dioscoridi L, Carrisi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634587>
40. **Spatiotemporal pattern of COVID-19 and government response in South Korea (as of May 31, 2020).** *Int J Infect Dis* 2020; Kim S, Castro MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634584>
41. **Estimation of the probable outbreak size of novel coronavirus (COVID-19) in social gathering events and industrial activities.** *Int J Infect Dis* 2020; Saidan MN, Shbool MA, Arabeyyat OS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634588>
42. **Distinctive trajectories of COVID-19 epidemic by age and gender: a retrospective modeling of the epidemic in South Korea.** *Int J Infect Dis* 2020; Yu X, Duan J, Jiang Y, Zhang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623081>
43. **Fear, xenophobia and collectivism as predictors of well-being during Coronavirus disease 2019: An empirical study from India.** *Int J Soc Psychiatry* 2020:20764020936323Ahuja KK, Banerjee D, Chaudhary K, Gidwani C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623927>
44. **COVID-19 pandemic lockdown: An emotional health perspective of Indians on Twitter.** *Int J Soc Psychiatry* 2020:20764020940741Chehal D, Gupta P, Gulati P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633185>
45. **The pandemic characteristics of 2019-nCoV: case-control study for severity and geographic locations for 2019-nCoV epidemics worldwide.** *Ital. J. Pediatr.* 2020; 46:94Ronchetti R, Bianco PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641092>
46. **Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.** *J Allergy Clin Immunol* 2020; Hosoki K, Chakraborty A, Sur S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624257>
47. **Distribution in Place of Death for Coronavirus 2019 (COVID-19)-Related Mortality in the United States.** *J Am Geriatr Soc* 2020; Chuzi S, Molsberry R, McCabe ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643800>
48. **COVID-19 Pandemic: How to Use Artificial Intelligence to Choose Non-Vulnerable Workers for Positions with the Highest Possible Levels of Exposure to the Novel Coronavirus.** *J Biomed Phys Eng* 2020; 10:383-386S ARM, S MJM, H P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637383>
49. **Knowledge, Attitudes and Practices Towards COVID-19: An Epidemiological Survey in North-Central Nigeria.** *J. Community Health* 2020; Reuben RC, Danladi MMA, Saleh DA, Ejembi PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638198>
50. **The COVID-19 Epidemic and the Prison System in Italy.** *J Correct Health Care* 2020:1078345820929733Cingolani M, Caraceni L, Cannovo N, Fedeli P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627645>
51. **Professional commitment to ethical discussions needed from epidemiologists in the COVID-19 pandemic.** *J. Epidemiol.* 2020; Matsui K, Yamamoto K, Inoue Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624521>
52. **Another invisible enemy indoors: COVID-19, human health, the home, and United States indoor air policy.** *J. Expo. Sci. Environ. Epidemiol.* 2020; Nwanaji-Enwerem JC, Allen JG, Beamer PI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641763>
53. **The Ambient Ozone and COVID-19 Transmissibility in China: A Data-Driven Ecological Study of 154 Cities.** *J Infect* 2020; Ran J, Zhao S, Han L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652165>
54. **Know your epidemic, know your response: understanding and responding to the heterogeneity of the COVID-19 epidemics across Southeast Asia.** *J Int AIDS Soc* 2020; 23:e25557Sohn AH, Phanuphak N, Baral S, Kamarulzaman A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623817>
55. **Household Transmission of SARS-CoV-2 from Adults to Children.** *J. Pediatr.* 2020; Yung CF, Kam KQ, Chong CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634405>
56. **Prenatal screening diagnosis and management in the era of coronavirus: the Sardinian experience.** *J. Perinat. Med.* 2020; Monni G, Corda V, Iuculano A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628637>
57. **COVID-19 Pandemic in India: Present Scenario and a Steep Climb Ahead.** *J. Prim. Care Community Health* 2020; 11:2150132720939402Pal R, Yadav U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644871>

58. **A familial cluster of coronavirus disease 2019 (COVID-19) caused by one family member during his asymptomatic incubation period.** J Public Health (Oxf) 2020; Sang H, Cui Y, Lai X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648578>
59. **Perceptions of public on the COVID-19 outbreak in Singapore: a qualitative content analysis.** J Public Health (Oxf) 2020; Shorey S, Ang E, Yamina A, Tam C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648577>
60. **Religious Cliche and Stigma: A Brief Response to Overlooked Barriers in COVID-19 Management.** J Relig Health 2020; Hashmi FK, Iqbal Q, Haque N, Saleem F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643082>
61. **A Look at the First Quarantined Community in the USA: Response of Religious Communal Organizations and Implications for Public Health During the COVID-19 Pandemic.** J Relig Health 2020; Weinberger-Litman SL, Litman L, Rosen Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651728>
62. **COVID-19 and Rural Harm Reduction Challenges in the U.S. Southern Mountains.** J Rural Health 2020; Ostrach B, Buer LM, Armbruster S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652621>
63. **How Much May COVID-19 School Closures Increase Childhood Obesity?** Obesity (Silver Spring) 2020; Workman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640077>
64. **Epidemiology of COVID-19 Infection in Oman: Analysis of the First 1304 Cases.** Oman Med. J. 2020; 35:e141Khamis F, Al Rashidi B, Al-Zakwani I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647593>
65. **The implications of silent transmission for the control of COVID-19 outbreaks.** Proc Natl Acad Sci U S A 2020; Moghadas SM, Fitzpatrick MC, Sah P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632012>
66. **Tracking the reach of COVID-19 kin loss with a bereavement multiplier applied to the United States.** Proc Natl Acad Sci U S A 2020; Verdery AM, Smith-Greenaway E, Margolis R, Daw J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651279>
67. **Working memory capacity predicts individual differences in social-distancing compliance during the COVID-19 pandemic in the United States.** Proc Natl Acad Sci U S A 2020; Xie W, Campbell S, Zhang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651280>
68. **Letter from the United States: A New York experience with COVID-19.** Respirology 2020; Schenck EJ, Turetz ML, Niederman MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627295>
69. **Contact tracing: Unearthing key epidemiological features of COVID-19.** SAGE Open Med Case Rep 2020; 8:2050313x20933483Ish P, Agrawal S, Goel AD, Gupta N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632351>
70. **Importance of early precautionary actions in avoiding the spread of COVID-19: Saudi Arabia as an Example.** Saudi Pharm J 2020; 28:898-902Alshammari TM, Altebainawi AF, Alenzi KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641902>
71. **Effect of the social distancing measures on the spread of COVID-19 in 10 highly infected countries.** Sci Total Environ 2020; 742:140430Thu TPB, Ngoc PNH, Hai NM, Tuan LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623158>
72. **[COVID-19. History repeats itself and we keep stumbling on the same stone].** Semerger 2020; Serrano-Cumplido A, Anton-Eguia Ortega PB, Ruiz Garcia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646730>
73. **Cardiopulmonary Considerations for High School Student-Athletes During the COVID-19 Pandemic: NFHS-AMSSM Guidance Statement.** Sports Health 2020:1941738120941490Drezner JA, Heinz WM, Asif IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640879>
74. **Potential transmission of SARS-CoV-2 on a flight from Singapore to Hangzhou, China: An epidemiological investigation.** Travel Med Infect Dis 2020:101816Chen J, He H, Cheng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645477>
75. **Coronavirus and Quarantine: Catalysts of Domestic Violence.** Violence Against Women 2020:1077801220935194Bouillon-Minois JB, Clinchamps M, Duthheil F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627703>
76. **Early Phase of the COVID-19 Outbreak in Hungary and Post-Lockdown Scenarios.** Viruses 2020; 12Rost G, Bartha FA, Bogya N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629880>

Management (55 articles)

1. **The role of the family physician in the fight against Coronavirus disease 2019 in Nigeria.** Afr J Prim Health Care Fam Med 2020; 12:e1-e3Oseni TIA, Agbede RO, Fatusin BB, Odewale MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634004>
2. **To keep a COVID-19-free hospital ward: mission possible?** Aging Clin. Exp. Res. 2020; Bo M, Brunetti E, Presta R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648228>
3. **Saliva ejector assisted laryngoscopy (SEAL) for protective intubation.** Am J Emerg Med 2020; Lin LW, Chong CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631772>
4. **Practical considerations in prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19.** Am. J. Health Syst. Pharm. 2020; Smith K, Krajewski KC, Krajewski MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628248>
5. **Palliative Care Team Involvement in Patients With COVID-19 in New York City.** Am. J. Hosp. Palliat. Care 2020:1049909120940986Obata R, Maeda T, Rizk D, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638632>
6. **Drape to Prevent Disease Transmission During Endotracheal Intubation.** Am. J. Infect. Control 2020; Emami N, Taner T, Ogundipe F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628982>
7. **COVID-19 Infection: Strategies on When to Discontinue Isolation, a retrospective study.** Am. J. Infect. Control 2020; Woodruff A, Walsh KL, Knight D, Irizarry-Alvarado JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634536>
8. **Establishing a standardized FEO emergency department: design and practice in dealing with COVID-19.** Ann Transl Med 2020; 8:749Chen T, Ma X, Zhou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647674>
9. **Airway management equipment and practice: time to optimise institutional, team, and personal preparedness.** Br J Anaesth 2020; Gibbins M, Kelly FE, Cook TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624185>

10. **Blood Component Use in Critical Care in Patients with COVID-19 Infection: A Single Centre Experience.** *Br. J. Haematol.* 2020; Doyle AJ, Danaee A, C IF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640484>
11. **CoVID-19 insights from transfusion medicine.** *Br. J. Haematol.* 2020; Flegel WA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640485>
12. **The 3 B's of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.** *Cancer* 2020; Kang JJ, Wong RJ, Sherman EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639615>
13. **Personalized therapy approach for hospitalized patients with COVID-19.** *Clin Infect Dis* 2020; Garcia-Vidal C, Moreno-Garcia E, Hernandez-Meneses M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649747>
14. **The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing ICU capacity.** *Clin Infect Dis* 2020; Nichols BE, Jamieson L, Zhang SRC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628744>
15. **Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic.** *Clin Res Cardiol* 2020; Scheller B, Vukadinovic D, Ewen S, Mahfoud F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623491>
16. **Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19.** *Crit Care* 2020; 24:412Laverdure F, Delaporte A, Bouteau A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646470>
17. **COVID-19: a hypothesis regarding the ventilation-perfusion mismatch.** *Crit Care* 2020; 24:395Santamarina MG, Boisier D, Contreras R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631389>
18. **Physician drug prescribing preferences and availability for ventilation of patients with COVID-19.** *Crit Care Resusc* 2020; Coombes ID, Dooley MJ, Townsend S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640769>
19. **Can vitamins and/or supplements provide hope against coronavirus?** *Drugs Context* 2020; 9Michienzi SM, Badowski ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636919>
20. **The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond.** *Endocrine* 2020; Tramontana F, Napoli N, El-Hajj Fuleihan G, Strollo R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632722>
21. **Percutaneous tracheostomy simulation training for ENT physicians in the treatment of COVID-19-positive patients.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Favier V, Kimmoun A, Gatin A, Gallet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624392>
22. **Percutaneous dilatational tracheostomy for saturating influx of COVID-19 patients: Experience of military ENT physicians deployed in Mulhouse, France.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Morvan JB, Riviere D, Danguy des Deserts M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631724>
23. **Clusters of COVID-19 in long-term care hospitals and facilities - Japan, Jan 15-May 9, 2020.** *Geriatr Gerontol Int* 2020; Iritani O, Okuno T, Hama D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634849>
24. **COVID-19 scenario modelling for the mitigation of capacity-dependent deaths in intensive care.** *Health Care Manag Sci* 2020; Wood RM, McWilliams CJ, Thomas MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642878>
25. **How New York City Health + Hospitals System-Wide Special Pathogens Program Responded to COVID-19.** *Health Secur* 2020; Madad S, Dhagat P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640848>
26. **Envisioning the Post-COVID-19, Pre-Vaccine Emergency Department.** *Health Secur* 2020; Natsui S, Silvestri DM, Salway RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640849>
27. **Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.** *Indian J. Clin. Biochem.* 2020; 35:373-375Manoharan Y, Haridas V, Vasanthakumar KC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641876>
28. **Health & Wellness Centers to Strengthen Primary Health Care in India: Concept, Progress and Ways Forward.** *Indian J Pediatr* 2020; Lahariya C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638338>
29. **Concerns for low-resource countries, with under-prepared intensive care units, facing the COVID-19 pandemic.** *Infect Dis Health* 2020; Elhadi M, Msherghi A, Alkeelani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631682>
30. **Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?** *J. Am. Coll. Nutr.* 2020:1-9Wallace TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649272>
31. **Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy.** *J Am Heart Assoc* 2020:e016948Sardu C, Maggi P, Messina V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633594>
32. **Aligning difficult airway guidelines with the anesthetic COVID-19 guidelines to develop a COVID-19 difficult airway strategy: a narrative review.** *J. Anesth.* 2020; Wong P, Lim WY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642840>
33. **COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.** *J. Clin. Hypertens. (Greenwich)* 2020; Kario K, Morisawa Y, Sukonthasarn A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643874>
34. **Knowledge, Attitude, and Practices Toward COVID-19 in Primary Healthcare Providers: A Cross-Sectional Study from Three Tertiary Care Hospitals of Peshawar, Pakistan.** *J. Community Health* 2020; Hussain I, Majeed A, Imran I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632645>
35. **Knowledge, Attitudes and Practices Towards COVID-19: An Epidemiological Survey in North-Central Nigeria.** *J. Community Health* 2020; Reuben RC, Danladi MMA, Saleh DA, Ejembi PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638198>
36. **Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria.** *J Dermatolog Treat* 2020:1-10Shanshal M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649228>
37. **COVID-19 in people living with diabetes: An international consensus.** *J. Diabetes Complications* 2020:107671Caballero AE, Ceriello A, Misra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651031>
38. **Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.** *J. Drug Target.* 2020:1-46Alvi MM, Sivasankaran S, Singh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643436>

39. **SARS-CoV-2 Infection in Febrile Neonates.** *J Pediatric Infect Dis Soc* 2020; Wardell H, Campbell JI, VanderPluym C, Dixit A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645175>
40. **Covid-19: A systemic disease treated with a wide-ranging approach: A case report.** *J. Popul. Ther. Clin. Pharmacol.* 2020; 27:e26-e30Massabeti R, Cipriani MS, Valenti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650356>
41. **Could DIZE be the answer to COVID-19?** *Maturitas* 2020; Qaradakh T, Gadanec L, Matsoukas J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636103>
42. **Australia's national COVID-19 primary care response.** *Med. J. Aust.* 2020; Desborough J, Hall Dykgraaf S, de Toca L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623740>
43. **Containment of the COVID-19 pandemic: My patient has a warning from his corona app - What should I do?** *MMW-Fortschritte der Medizin* 2020; 162:35Urbanek M.
44. **Triage - Examining, sorting and deciding in the COVID-19 pandemic: Medicolegal aspects.** *Notarzt* 2020; 36:130-131Kern BR, Peters M.
45. **Dispatches from the frontlines: A critical care nurse's response to COVID19.** *Nurs. Outlook* 2020; Allen JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624237>
46. **GEICAM Guidelines for the Management of Patients with Breast Cancer During Spain's COVID-19 Pandemic.** *Oncologist* 2020; Martin M, Guerrero-Zotano A, Montero A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652782>
47. **Dying patients with COVID-19: What should Hospital Palliative Care Teams (HPCTs) be prepared for?** *Palliat Support Care* 2020:1-3Anneser J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631469>
48. **Goals of care and COVID-19: A GOOD framework for dealing with uncertainty.** *Palliat Support Care* 2020:1-3Petriceks AH, Schwartz AWN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631459>
49. **Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndrome.** *Perfusion* 2020:267659120939757Lewis D, Fisler G, Schneider J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643551>
50. **Consideration of Tranexamic Acid Administration to COVID-19 Patients.** *Physiol Rev* 2020; 100:1595-1596Ogawa H, Asakura H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639181>
51. **Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2.** *Respir. Physiol. Neurobiol.* 2020:103489Pagano A, Porta G, Bosso G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629100>
52. **Alternative management of Covid-19 infection.** *Scott. Med. J.* 2020:36933020941497Atrah HI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638647>
53. **NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection.** *Therapie* 2020; Cumhur Cure M, Kucuk A, Cure E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636031>
54. **SARS-CoV2 and immunosuppression: a double-edged sword.** *Transpl Infect Dis* 2020:e13404Lai Q, Spoletini G, Bianco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639598>
55. **Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.** *Trials* 2020; 21:632Saiz-Rodriguez M, Pena T, Lazaro L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646502>

Mental – public health (55 articles)

1. **The role of the family physician in the fight against Coronavirus disease 2019 in Nigeria.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3Oseni TIA, Agbede RO, Fatusin BB, Odewale MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634004>
2. **To keep a COVID-19-free hospital ward: mission possible?** *Aging Clin. Exp. Res.* 2020; Bo M, Brunetti E, Presta R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648228>
3. **Saliva ejector assisted laryngoscopy (SEAL) for protective intubation.** *Am J Emerg Med* 2020; Lin LW, Chong CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631772>
4. **Practical considerations in prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19.** *Am. J. Health Syst. Pharm.* 2020; Smith K, Krajewski KC, Krajewski MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628248>
5. **Palliative Care Team Involvement in Patients With COVID-19 in New York City.** *Am. J. Hosp. Palliat. Care* 2020:1049909120940986Obata R, Maeda T, Rizk D, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638632>
6. **Drape to Prevent Disease Transmission During Endotracheal Intubation.** *Am. J. Infect. Control* 2020; Emami N, Taner T, Ogundipe F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628982>
7. **COVID-19 Infection: Strategies on When to Discontinue Isolation, a retrospective study.** *Am. J. Infect. Control* 2020; Woodruff A, Walsh KL, Knight D, Irizarry-Alvarado JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634536>
8. **Establishing a standardized FEO emergency department: design and practice in dealing with COVID-19.** *Ann Transl Med* 2020; 8:749Chen T, Ma X, Zhou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647674>
9. **Airway management equipment and practice: time to optimise institutional, team, and personal preparedness.** *Br J Anaesth* 2020; Gibbins M, Kelly FE, Cook TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624185>
10. **Blood Component Use in Critical Care in Patients with COVID-19 Infection: A Single Centre Experience.** *Br. J. Haematol.* 2020; Doyle AJ, Danaee A, C IF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640484>
11. **CoVID-19 insights from transfusion medicine.** *Br. J. Haematol.* 2020; Flegel WA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640485>
12. **The 3 B's of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.** *Cancer* 2020; Kang JJ, Wong RJ, Sherman EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639615>
13. **Personalized therapy approach for hospitalized patients with COVID-19.** *Clin Infect Dis* 2020; Garcia-Vidal C, Moreno-Garcia E, Hernandez-Meneses M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?>

term=32649747

14. **The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing ICU capacity.** *Clin Infect Dis* 2020; Nichols BE, Jamieson L, Zhang SRC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628744>
15. **Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic.** *Clin Res Cardiol* 2020; Scheller B, Vukadinovic D, Ewen S, Mahfoud F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623491>
16. **Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19.** *Crit Care* 2020; 24:412Laverdure F, Delaporte A, Bouteau A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646470>
17. **COVID-19: a hypothesis regarding the ventilation-perfusion mismatch.** *Crit Care* 2020; 24:395Santamarina MG, Boisier D, Contreras R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631389>
18. **Physician drug prescribing preferences and availability for ventilation of patients with COVID-19.** *Crit Care Resusc* 2020; Coombes ID, Dooley MJ, Townsend S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640769>
19. **Can vitamins and/or supplements provide hope against coronavirus?** *Drugs Context* 2020; 9Michienzi SM, Badowski ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636919>
20. **The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond.** *Endocrine* 2020; Tramontana F, Napoli N, El-Hajj Fuleihan G, Strollo R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632722>
21. **Percutaneous tracheostomy simulation training for ENT physicians in the treatment of COVID-19-positive patients.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Favier V, Kimmoun A, Gatin A, Gallet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624392>
22. **Percutaneous dilatational tracheostomy for saturating influx of COVID-19 patients: Experience of military ENT physicians deployed in Mulhouse, France.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Morvan JB, Riviere D, Danguy des Deserts M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631724>
23. **Clusters of COVID-19 in long-term care hospitals and facilities - Japan, Jan 15-May 9, 2020.** *Geriatr Gerontol Int* 2020; Iritani O, Okuno T, Hama D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634849>
24. **COVID-19 scenario modelling for the mitigation of capacity-dependent deaths in intensive care.** *Health Care Manag Sci* 2020; Wood RM, McWilliams CJ, Thomas MJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642878>
25. **How New York City Health + Hospitals System-Wide Special Pathogens Program Responded to COVID-19.** *Health Secur* 2020; Madad S, Dhagat P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640848>
26. **Envisioning the Post-COVID-19, Pre-Vaccine Emergency Department.** *Health Secur* 2020; Natsui S, Silvestri DM, Salway RJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640849>
27. **Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.** *Indian J. Clin. Biochem.* 2020; 35:373-375Manoharan Y, Haridas V, Vasanthakumar KC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641876>
28. **Health & Wellness Centers to Strengthen Primary Health Care in India: Concept, Progress and Ways Forward.** *Indian J Pediatr* 2020; Lahariya C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638338>
29. **Concerns for low-resource countries, with under-prepared intensive care units, facing the COVID-19 pandemic.** *Infect Dis Health* 2020; Elhadi M, Msherghi A, Alkeelani M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631682>
30. **Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?** *J. Am. Coll. Nutr.* 2020; 1-9Wallace TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649272>
31. **Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy.** *J Am Heart Assoc* 2020:e016948Sardu C, Maggi P, Messina V *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633594>
32. **Aligning difficult airway guidelines with the anesthetic COVID-19 guidelines to develop a COVID-19 difficult airway strategy: a narrative review.** *J. Anesth.* 2020; Wong P, Lim WY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642840>
33. **COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.** *J. Clin. Hypertens. (Greenwich)* 2020; Kario K, Morisawa Y, Sukonthasarn A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643874>
34. **Knowledge, Attitude, and Practices Toward COVID-19 in Primary Healthcare Providers: A Cross-Sectional Study from Three Tertiary Care Hospitals of Peshawar, Pakistan.** *J. Community Health* 2020; Hussain I, Majeed A, Imran I *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632645>
35. **Knowledge, Attitudes and Practices Towards COVID-19: An Epidemiological Survey in North-Central Nigeria.** *J. Community Health* 2020; Reuben RC, Danladi MMA, Saleh DA, Ejembi PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638198>
36. **Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria.** *J Dermatolog Treat* 2020; 1-10Shanshal M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649228>
37. **COVID-19 in people living with diabetes: An international consensus.** *J. Diabetes Complications* 2020; 107671Caballero AE, Ceriello A, Misra A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651031>
38. **Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.** *J. Drug Target.* 2020; 1-46Alvi MM, Sivasankaran S, Singh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643436>
39. **SARS-CoV-2 Infection in Febrile Neonates.** *J Pediatr Infect Dis Soc* 2020; Wardell H, Campbell JI, VanderPluym C, Dixit A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645175>
40. **Covid-19: A systemic disease treated with a wide-ranging approach: A case report.** *J. Popul. Ther. Clin. Pharmacol.* 2020; 27:e26-e30Massabeti R, Cipriani MS, Valenti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650356>
41. **Could DIZE be the answer to COVID-19?** *Maturitas* 2020; Qaradakh T, Gadanec L, Matsoukas J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636103>
42. **Australia's national COVID-19 primary care response.** *Med. J. Aust.* 2020; Desborough J, Hall Dykgraaf S, de Toca L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623740>
43. **Containment of the COVID-19 pandemic: My patient has a warning from his corona app - What should I do?** *MMW-Fortschritte der Medizin* 2020; 162:35Urbanek M.

44. **Triage - Examining, sorting and deciding in the COVID-19 pandemic: Medicolegal aspects.** *Notarzt* 2020; 36:130-131 Kern BR, Peters M.
45. **Dispatches from the frontlines: A critical care nurse's response to COVID19.** *Nurs. Outlook* 2020; Allen JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624237>
46. **GEICAM Guidelines for the Management of Patients with Breast Cancer During Spain's COVID-19 Pandemic.** *Oncologist* 2020; Martin M, Guerrero-Zotano A, Montero A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652782>
47. **Dying patients with COVID-19: What should Hospital Palliative Care Teams (HPCTs) be prepared for?** *Palliat Support Care* 2020:1-3 Anneser J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631469>
48. **Goals of care and COVID-19: A GOOD framework for dealing with uncertainty.** *Palliat Support Care* 2020:1-3 Petriceks AH, Schwartz AWN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631459>
49. **Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndrome.** *Perfusion* 2020:267659120939757 Lewis D, Fisler G, Schneider J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643551>
50. **Consideration of Tranexamic Acid Administration to COVID-19 Patients.** *Physiol Rev* 2020; 100:1595-1596 Ogawa H, Asakura H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639181>
51. **Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2.** *Respir. Physiol. Neurobiol.* 2020:103489 Pagano A, Porta G, Bosso G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629100>
52. **Alternative management of Covid-19 infection.** *Scott. Med. J.* 2020:36933020941497 Atrah HI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638647>
53. **NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection.** *Therapie* 2020; Cumhur Cure M, Kucuk A, Cure E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636031>
54. **SARS-CoV2 and immunosuppression: a double-edged sword.** *Transpl Infect Dis* 2020:e13404 Lai Q, Spoletini G, Bianco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639598>
55. **Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.** *Trials* 2020; 21:632 Saiz-Rodriguez M, Pena T, Lazaro L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646502>

Meta-analyses - systematic reviews (7 articles)

1. **Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis.** *Ann Gastroenterol* 2020; 33:355-365 Rokkas T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624655>
2. **Renal complications in COVID-19: A systematic review and meta-analysis.** *Ann. Med.* 2020:1-18 Kunutsor SK, Laukkanen JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643418>
3. **Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis.** *Hepatol Int* 2020; Kumar MP, Mishra S, Jha DK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623633>
4. **A Comparison of Mortality-related Risk Factors of COVID-19, SARS, and MERS: A Systematic Review and Meta-analysis.** *J Infect* 2020; Lu L, Zhong W, Bian Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634459>
5. **Mental Health During the Covid-19 Outbreak in China: a Meta-Analysis.** *Psychiatr. Q.* 2020; Ren X, Huang W, Pan H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642822>
6. **Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis.** *Ther. Adv. Chronic Dis.* 2020; 11:2040622320935765 Farsalinos K, Barbouni A, Poulas K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637059>
7. **Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.** *Travel Med Infect Dis* 2020:101812 Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645478>

Mortality (22 articles)

1. **Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China.** *Aging (Albany NY)* 2020; 12 Liu X, Zheng X, Liu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628642>
2. **Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.** *Cancers (Basel)* 2020; 12 Pinato DJ, Lee AJX, Biello F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650523>
3. **Distinct clinical characteristics and risk factors for mortality in female COVID-19 inpatients: a sex-stratified large-scale cohort study in Wuhan, China.** *Clin Infect Dis* 2020; Chen J, Bai H, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634830>
4. **Development and Validation of a Nomogram for Assessing Survival in Patients with COVID-19 Pneumonia.** *Clin Infect Dis* 2020; Dong YM, Sun J, Li YX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649738>
5. **Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study.** *Clin Infect Dis* 2020; Kragholm K, Andersen MP, Gerds TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634827>
6. **Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China.** *Crit Care* 2020; 24:394 Xu J, Yang X, Yang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631393>
7. **A Fatal Case of Coronavirus Disease 2019 (COVID-19) in a Patient With Idiopathic Pulmonary Fibrosis.** *Cureus* 2020; 12:e8432 Rajasurya V, Gunasekaran K, Damarla V, Kolluru A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642347>
8. **Differential mortality in COVID-19 patients from India and western countries.** *Diabetes Metab Syndr* 2020; 14:1037-1041 Jain VK, Iyengar K, Vaish A, Vaishya R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642347>

term=32640415

9. **Risk Factors for Mortality among COVID-19 Patients.** *Diabetes Res Clin Pract* 2020;108293Albitar O, Ballouze R, Ping Ooi J, Maisharah Sheikh Ghadzi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623035>
10. **Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease.** *Diabetol. Metab. Syndr.* 2020; 12:57Rastad H, Karim H, Ejtahed HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641974>
11. **Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020.** *Euro Surveill* 2020; 25Vestergaard LS, Nielsen J, Richter L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643601>
12. **SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype.** *Gene* 2020;144944Yamamoto N, Ariumi Y, Nishida N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628976>
13. **COVID-19 scenario modelling for the mitigation of capacity-dependent deaths in intensive care.** *Health Care Manag Sci* 2020; Wood RM, McWilliams CJ, Thomas MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642878>
14. **Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.** *Int J Infect Dis* 2020; Arshad S, Kilgore P, Chaudhry ZS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623082>
15. **Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID-19.** *J Am Geriatr Soc* 2020; Brouns SH, Bruggemann R, Linkens A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633418>
16. **Distribution in Place of Death for Coronavirus 2019 (COVID-19)-Related Mortality in the United States.** *J Am Geriatr Soc* 2020; Chuzi S, Molsberry R, McCabe ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643800>
17. **Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.** *J Autoimmun* 2020;102512Morrison AR, Johnson JM, Griebe KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646770>
18. **A Comparison of Mortality-related Risk Factors of COVID-19, SARS, and MERS: A Systematic Review and Meta-analysis.** *J Infect* 2020; Lu L, Zhong W, Bian Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634459>
19. **The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data.** *J Korean Med Sci* 2020; 35:e243Kim DW, Byeon KH, Kim J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627443>
20. **Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.** *Neurol Sci* 2020; Hwang JM, Kim JH, Park JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643133>
21. **Dying patients with COVID-19: What should Hospital Palliative Care Teams (HPCTs) be prepared for?** *Palliat Support Care* 2020;1-3Anneser J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631469>
22. **Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:614Beigmohammadi MT, Bitarafan S, Hoseindokht A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631405>

Online – IT – Apps (26 articles)

1. **Evaluation of teleconsultation system in the urological patient during the COVID-19 pandemic.** *Actas Urol. Esp.* 2020; Leibar Tamayo A, Linares Espinos E, Rios Gonzalez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650954>
2. **Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019.** *Agging (Albany NY)* 2020; 12Yu M, Ye Z, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628131>
3. **(Vi)-rushed Into Online Group Schema Therapy Based Day-Treatment for Older Adults by the COVID-19 Outbreak in the Netherlands.** *Am J Geriatr Psychiatry* 2020; van Dijk SDM, Bouman R, Folmer EH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622730>
4. **Death in the ICU from COVID-19: more research on its effects on families needed.** *Br J Anaesth* 2020; Molokhia A, Khaliq W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622466>
5. **Telephone based survey in adults with congenital heart disease during COVID-19 pandemic.** *Cardiol J* 2020; Frogoudaki AA, Farmakis D, Tsounis D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643139>
6. **Global Storm of Stress-Related Psychopathological Symptoms: A Brief Overview on the Usefulness of Virtual Reality in Facing the Mental Health Impact of COVID-19.** *Cyberpsychol Behav Soc Netw* 2020; Imperatori C, Dakanalas A, Farina B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640852>
7. **Application of Artificial Intelligence in COVID-19 drug repurposing.** *Diabetes Metab Syndr* 2020; 14:1027-1031Mohanty S, Harun Ai Rashid M, Mridul M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634717>
8. **Telemedicine for ENT: Effect on quality of care during Covid-19 pandemic.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Fieux M, Duret S, Bawazeer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624390>
9. **Impact of COVID-19 epidemic on live online dental continuing education.** *Eur. J. Dent. Educ.* 2020; Liu X, Zhou J, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648989>
10. **The Effect of the COVID-19 Pandemic on Physicians' Use and Perception of Telehealth: The Case of Lebanon.** *Int J Environ Res Public Health* 2020; 17Helou S, El Helou E, Abou-Khalil V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640652>
11. **A Proposal for Multidisciplinary Tele-Rehabilitation in the Assessment and Rehabilitation of COVID-19 Survivors.** *Int J Environ Res Public Health* 2020; 17Salawu A, Green A, Crooks MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645876>
12. **Redesigning Portable Health Clinic Platform as a Remote Healthcare System to Tackle COVID-19 Pandemic Situation in Unreached Communities.** *Int J Environ Res Public Health* 2020; 17Sampa MB, Hoque MR, Islam R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629963>
13. **Artificial intelligence and COVID-19: A multidisciplinary approach.** *Integr Med Res* 2020; 9:100434Ahuja AS, Reddy VP, Marques O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632356>

14. **The evaluation of online course of Traditional Chinese Medicine for MBBS international students during the COVID-19 epidemic period.** *Integr Med Res* 2020; 9:100449Zhang Q, He YJ, Zhu YH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632357>
15. **Exploring the adoption of telemedicine and virtual software for care of outpatients during and after COVID-19 pandemic.** *Ir. J. Med. Sci.* 2020; Bokolo AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642981>
16. **Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.** *J. Alzheimers Dis.* 2020; Capozzo R, Zoccollella S, Frisullo ME *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651328>
17. **National Geriatric Network Rapidly Addresses Trainee Telehealth Needs in Response to COVID-19.** *J Am Geriatr Soc* 2020; Nearing KA, Lum HD, Dang S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639578>
18. **COVID-19 Pandemic: How to Use Artificial Intelligence to Choose Non-Vulnerable Workers for Positions with the Highest Possible Levels of Exposure to the Novel Coronavirus.** *J Biomed Phys Eng* 2020; 10:383-386S ARM, S MJM, H P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637383>
19. **Implementation of Home-Based Telemental Health in a Large Child Psychiatry Department During the COVID-19 Crisis.** *J. Child Adolesc. Psychopharmacol.* 2020; Sharma A, Sasser T, Schoenfelder Gonzalez E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639849>
20. **Building Telemedicine Capacity for Trainees During the Novel Coronavirus Outbreak: a Case Study and Lessons Learned.** *J Gen Intern Med* 2020; Lawrence K, Hanley K, Adams J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642929>
21. **Systematic review of artificial intelligence techniques in the detection and classification of COVID-19 medical images in terms of evaluation and benchmarking: Taxonomy analysis, challenges, future solutions and methodological aspects.** *J Infect Public Health* 2020; Albahri OS, Zaidan AA, Albahri AS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646771>
22. **Assessment of YouTube as an Educational Tool in Teaching Key Indicator Cases in Otolaryngology During the COVID-19 Pandemic and Beyond: Neck Dissection.** *J Surg Educ* 2020; Luu NN, Yver CM, Douglas JE *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646815>
23. **Telemedicine and Neurological Practice in the COVID-19 Era.** *Neurol. India* 2020; 68:555-559Ganapathy K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643663>
24. **Launching a public statewide tele(oral)medicine service in Brazil during COVID-19 pandemic.** *Oral Dis* 2020; Meurer MI, von Wangenheim A, Zimmermann C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623802>
25. **The paediatric weight management office visit via telemedicine: pre- to post-COVID-19 pandemic.** *Pediatr. Obes.* 2020; O'Hara VM, Johnston SV, Browne NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627434>
26. **Rapid Scaling Up of Telehealth Treatment for Tobacco-Dependent Cancer Patients During the COVID-19 Outbreak in New York City.** *Telemed J E Health* 2020:1-10Kotsen C, Dilip D, Carter-Harris L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649266>

Other – Miscellaneous (25 articles)

1. **What is the best timing for healthcare workers infected COVID-19 to return to work?** *Am. J. Infect. Control* 2020; Wang J, Lee YF, Zhou M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628983>
2. **Greetings from the front lines, when all the world is the front.** *Cancer* 2020; Khuri FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648590>
3. **Surprise Medical Billing: Compelling Need to Address Uncertainty, Anxiety, and Financial Peril for Patients.** *Circulation* 2020; 142:e1-e2Churchwell K, Roll JT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628553>
4. **Dataset of ex-pat teachers in Southeast Asia's intention to leave due to the COVID-19 pandemic.** *Data Brief* 2020; 31:105913Hoang AD, Ta NT, Nguyen YC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632376>
5. **A joint dataset of official COVID-19 reports and the governance, trade and competitiveness indicators of World Bank group platforms.** *Data Brief* 2020; 31:105881Kurbucz MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632375>
6. **Balanced diet is a major casualty in COVID-19.** *Diabetes Metab Syndr* 2020; 14:1085-1086Jayawardena R, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652495>
7. **Extensively drug-resistant tuberculosis in the time of COVID-19-how has the landscape changed for Pakistan?** *Disaster Med Public Health Prep* 2020:1-4Islam M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635960>
8. **The impact of COVID-19 as a necessary evil on air pollution in India during the lockdown.** *Environ Pollut* 2020; 266:115080Sarfraz M, Shehzad K, Shah SGM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634726>
9. **The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.** *Front Med* 2020; Li Q, Wang H, Li X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651936>
10. **Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?** *Front. Microbiol.* 2020; 11:1476Nghochuzie NN, Olwal CO, Udoakang AJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32625198>
11. **Why we should all be more careful in drawing conclusions about how COVID-19 is changing drug markets.** *Int. J. Drug Policy* 2020:102834Giommoni L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646713>
12. **Fine-Grained Spatiotemporal Analysis of the Impact of Restricting Factories, Motor Vehicles, and Fireworks on Air Pollution.** *Int J Environ Res Public Health* 2020; 17Yang M, Fan H, Zhao K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635543>
13. **Geostatistical COVID-19 infection risk maps for Portugal.** *Int J Health Geogr* 2020; 19:25Azevedo L, Pereira MJ, Ribeiro MC, Soares A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631358>
14. **Ayurvedic clinical profile of COVID-19 - A preliminary report.** *J. Ayurveda Integr. Med.* 2020; Puthiyedath R, Kataria S, Payyappallimana U *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624376>

15. **International Collaboration.** *J Dermatolog Treat* 2020;1-3Goldman MP, Murrell DF, Al-Mutairi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646257>
16. **Richard Allen Williams, M.D.: a Career Fighting Disparities and Fostering Equity.** *J Racial Ethn Health Disparities* 2020; Bailey RK, Saldana AM, Saldana AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632825>
17. **Nipah@20: Lessons Learned from Another Virus with Pandemic Potential.** *mSphere* 2020; 5Gomez Roman R, Wang LF, Lee B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641430>
18. **Triage - Examining, sorting and deciding in the COVID-19 pandemic: Medicolegal aspects.** *Notarzt* 2020; 36:130-131Kern BR, Peters M.
19. **A call to action to address COVID-19-induced global food insecurity to prevent hunger, malnutrition, and eating pathology.** *Nutr. Rev.* 2020; Paslakis G, Dimitropoulos G, Katzman DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651592>
20. **COVID-19 Science Policy, Experts, and Publics: Why Epistemic Democracy Matters in Ecological Crises.** *OMICS* 2020; Boschele M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644877>
21. **The impact of COVID-19 on small business outcomes and expectations.** *Proc Natl Acad Sci U S A* 2020; Bartik AW, Bertrand M, Cullen Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651281>
22. **To take care of those on the front line against Covid-19: Is it possible to limit medical liability?** *Sci. Justice* 2020; 60:311-312Tozzo P, Politi C, Gabbin A, Caenazzo L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650933>
23. **Air pollution in Ontario, Canada during the COVID-19 State of Emergency.** *Sci Total Environ* 2020; 742:140516Adams MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629257>
24. **Impact of city lockdown on the air quality of COVID-19-hit of Wuhan city.** *Sci Total Environ* 2020; 742:140556Lian X, Huang J, Huang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634686>
25. **COVID-19 and ethical preparedness?** *Wien. Klin. Wochenschr.* 2020; Druml C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643017>

Pathology (9 articles)

1. **The Anatomic Pathology laboratory adjustments in the era of COVID-19 pandemic: The experience of a laboratory in a Portuguese central hospital.** *Ann. Diagn. Pathol.* 2020; 48:151560Lamas NJ, Esteves S, Alves JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645559>
2. **Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** *Exp. Biol. Med. (Maywood)* 2020:1535370220942126Afewerky HK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635753>
3. **Caution in Identifying Coronaviruses by Electron Microscopy.** *J Am Soc Nephrol* 2020; Goldsmith CS, Miller SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651224>
4. **Use of whole slide imaging (WSI) for distance teaching.** *J. Clin. Pathol.* 2020; Evans AJ, Depeiza N, Allen SG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646928>
5. **A review on histotechnology practices in COVID-19 pathology investigations.** *J Histotechnol* 2020:1-6Malloy S, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643596>
6. **The Impact of the COVID-19 Pandemic and the Associated Belgian Governmental Measures on Cancer Screening, Surgical Pathology and Cytopathology.** *Pathobiology* 2020:1-10de Pelsemaeker MC, Guiot Y, Vanderveken J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634799>
7. **The first COVID-19 autopsy in Spain performed during the early stages of the pandemic.** *Rev Esp Patol* 2020; 53:182-187. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650969>
8. **Autopsy findings from the first known death from Severe Acute Respiratory Syndrome SARS-CoV-2 in Spain.** *Rev Esp Patol* 2020; 53:188-192Navarro Conde P, Alemany Monraval P, Medina Medina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650970>
9. **Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists.** *Virchows Arch.* 2020; Calabrese F, Pezzuto F, Fortarezza F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642842>

Protection (44 articles)

1. **To keep a COVID-19-free hospital ward: mission possible?** *Aging Clin. Exp. Res.* 2020; Bo M, Brunetti E, Presta R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648228>
2. **Saliva ejector assisted laryngoscopy (SEAL) for protective intubation.** *Am J Emerg Med* 2020; Lin LW, Chong CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631772>
3. **Drape to Prevent Disease Transmission During Endotracheal Intubation.** *Am. J. Infect. Control* 2020; Emami N, Taner T, Ogundipe F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628982>
4. **Disinfection of N95 masks artificially contaminated with SARS-CoV-2 and ESKAPE bacteria using hydrogen peroxide plasma: impact on the reutilization of disposable devices.** *Am. J. Infect. Control* 2020; Ibanez-Cervantes G, Bravata-Alcantara JC, Najera-Cortes AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645473>
5. **Environmental Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from Medical Equipment in Long-Term Care Facilities undergoing COVID-19 Outbreaks.** *Am. J. Infect. Control* 2020; Nelson A, Kassimatis J, Estoque J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645474>
6. **Infection Control in Dental Anesthesiology: A Time for Preliminary Reconsideration of Current Practices.** *Anesth. Prog.* 2020; 67:109-120Tom J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633770>
7. **Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19.** *Antimicrob Resist Infect Control* 2020; 9:100Sommerstein R, Fux CA, Vuichard-Gysin D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631450>
8. **Rapid clearing of aerosol in an intubation box by vacuum filtration.** *Br J Anaesth* 2020; Hellman S, Chen GH, Irie T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650953>
9. **It is Time to Address Airborne Transmission of COVID-19.** *Clin Infect Dis* 2020; Morawska L, Milton DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628269>

10. **Optimising benefits of testing key workers for infection with SARS-CoV-2: A mathematical modelling analysis.** *Clin Infect Dis* 2020; Sandmann FG, White PJ, Ramsay M, Jit M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634823>
11. **Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London.** *Clin Infect Dis* 2020; Zhou J, Otter JA, Price JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634826>
12. **Disposable aluminum covering for electrodes during nerve conduction studies in COVID-19 patients.** *Clin. Neurol. Neurosurg.* 2020; 195:106064 Takata T, Kobara H, Deguchi K, Masaki T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652395>
13. **Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic.** *Clin Res Cardiol* 2020; Scheller B, Vukadinovic D, Ewen S, Mahfoud F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623491>
14. **Laparoscopic Pneumoperitoneum Escape and Contamination during Surgery using the Airseal Insufflation System: Video Vignette.** *Colorectal Dis* 2020; Dalli J, Khan MF, Nolan K, Cahill RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644263>
15. **Importance of corneal organ culture in donors with possible SARS-CoV-2 infections.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Thaler S, Schindler M, Iftner T *et al.*
16. **Protection and response of a tertiary hospital in South Korea to the COVID-19 outbreak.** *Disaster Med Public Health Prep* 2020:1-14 Shi HJ, Lee JB, Choi MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32624085>
17. **Effectiveness of Cloth Masks for Protection Against Severe Acute Respiratory Syndrome Coronavirus 2.** *Emerg Infect Dis* 2020; 26 Chughtai AA, Seale H, Macintyre CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639930>
18. **Prevention and control of COVID-19 in nursing homes, orphanages, and prisons.** *Environ Pollut* 2020; 266:115161 Wang J, Yang W, Pan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645554>
19. **Transmission of SARS-CoV-2: an update of current literature.** *Eur J Clin Microbiol Infect Dis* 2020; Patel KP, Vunnam SR, Patel PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638221>
20. **Assessment of SARS-CoV-2 in human semen-a cohort study.** *Fertil. Steril.* 2020; Holtmann N, Edimiris P, Andree M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650948>
21. **A proof of concept study: Esophagogastroduodenoscopy is an aerosol-generating procedure and continuous oral suction during the procedure reduces the amount of aerosol generated.** *Gastroenterology* 2020; Chan SM, Ma TW, Ka-Chun Chong M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649933>
22. **Shelter-In-Place Orders Reduced COVID-19 Mortality And Reduced The Rate Of Growth In Hospitalizations.** *Health Aff (Millwood)* 2020:101377 hithaff202000719 Lyu W, Wehby GL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644825>
23. **Strategies for the Prevention of the Intra-Hospital Transmission of COVID-19: A Retrospective Cohort Study.** *Healthcare (Basel)* 2020; 8 Chang MC, Hur J, Park D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635290>
24. **Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.** *Infect Dis Ther* 2020; Anderson DE, Sivalingam V, Kang AEZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643111>
25. **Review of Indoor Aerosol Generation, Transport and Control in the Context of COVID-19.** *Int Forum Allergy Rhinol* 2020; Kohanski MA, Lo LJ, Waring MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652898>
26. **Infection Control in Dental Practice During the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17 Amato A, Caggiano M, Amato M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32630735>
27. **COVID-19 among Health Workers in Germany and Malaysia.** *Int J Environ Res Public Health* 2020; 17 Nienhaus A, Hod R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645826>
28. **Covid-19 exposure risk for family members of healthcare workers: an observational study.** *Int J Infect Dis* 2020; Dioscoridi L, Carrisi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634587>
29. **Conducting exposure and response prevention treatment for contamination fears during COVID-19: The behavioral immune system impact on clinician approaches to treatment.** *J Anxiety Disord.* 2020; 74:102270 McKay D, Minaya C, Storch EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650220>
30. **Increasing handwashing in young children: A brief review.** *J. Appl. Behav. Anal.* 2020; Jess RL, Dozier CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639051>
31. **Another invisible enemy indoors: COVID-19, human health, the home, and United States indoor air policy.** *J. Expo. Sci. Environ. Epidemiol.* 2020; Nwanaji-Enwerem JC, Allen JG, Beamer PI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641763>
32. **Technics to put on and remove personal protective equipment before surgical or obstetrical procedure in suspected or infected COVID-19 patients (with video).** *J Gynecol Obstet Hum Reprod* 2020:101859 Nohuz E, Atallah A, Cerruto E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652303>
33. **Dry heat and microwave generated steam protocols for the rapid decontamination of respiratory personal protective equipment in response to COVID-19-related shortages.** *J Hosp Infect* 2020; Pascoe MJ, Robertson A, Crayford A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652212>
34. **Reusing N95 (or P2) masks: current evidence and urgent research questions.** *Med. J. Aust.* 2020; Branley JM, Polkinghorne A, Gilbert GL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623732>
35. **Nurse Staffing and Coronavirus Infections in California Nursing Homes.** *Policy Polit. Nurs. Pract.* 2020:1527154420938707 Harrington C, Ross L, Chapman S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635838>
36. **ERCP and SARS-COV-2: an urgent procedure that should be immune.** *Scand. J. Gastroenterol.* 2020:1-30 Grady J, Leyden J, MacMathuna P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643467>
37. **Snowballing transmission of COVID-19 (SARS-CoV-2) through wastewater: Any sustainable preventive measures to curtail the scourge in low-income countries?** *Sci Total Environ* 2020; 742:140680 Adelodun B, Ajibade FO, Ibrahim RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629273>
38. **Environmental contamination by SARS-CoV-2 of an imported case during incubation period.** *Sci Total Environ* 2020; 742:140620 Hu X, Xing Y, Ni W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640392>

39. **COVID-19 and frequent use of hand sanitizers; human health and environmental hazards by exposure pathways.** *Sci Total Environ* 2020; 742:140561Mahmood A, Eqan M, Pervez S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623176>
40. **Development of a Sterile Personal Protective Equipment Donning and Doffing Procedure to Protect Surgical Teams from SARS-CoV-2 Exposure during the COVID-19 Pandemic.** *Surg Infect (Larchmt)* 2020; Evans HL, Thomas CS, Bell LH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628871>
41. **Knowledge and Attitudes Among Hospital Pharmacists About COVID-19.** *Turk J Pharm Sci* 2020; 17:242-248Kara E, Demlirkan K, Unal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636699>
42. **General Surgery Operating Room Practice in Patients with COVID-19.** *Turk J Surg* 2020; 36:i-vKaraca AS, Ozmen MM, AD UC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637887>
43. **Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?** *Viruses* 2020; 12Pastorino B, Touret F, Gilles M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646015>
44. **Coronaviruses widespread on nonliving surfaces: important questions and promising answers.** *Z Naturforsch C J Biosci* 2020; Deyab MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623382>

Pulmonary disease (10 articles)

1. **RV Infections in Asthmatics Increase ACE2 Expression and Cytokine Pathways Implicated in COVID-19.** *Am J Respir Crit Care Med* 2020; Chang EH, Willis AL, Romanoski CE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649217>
2. **Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection risk during elective peri-operative care: a narrative review.** *Anaesthesia* 2020; Schutzer-Weissmann J, Magee DJ, Farquhar-Smith P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652529>
3. **COVID-19-associated pneumomediastinum.** *Clin Med (Lond)* 2020; Goldman N, Ketheeswaran B, Wilson H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628129>
4. **Reduction in healthcare-associated respiratory viral infections during a COVID-19 outbreak.** *Clin Microbiol Infect* 2020; Wee LE, Conceicao EP, Sim XYJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622953>
5. **A Fatal Case of Coronavirus Disease 2019 (COVID-19) in a Patient With Idiopathic Pulmonary Fibrosis.** *Cureus* 2020; 12:e8432Rajasurya V, Gunasekaran K, Damarla V, Kolluru A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642347>
6. **Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain.** *EClinicalMedicine* 2020; 23:100407San-Juan R, Barbero P, Fernandez-Ruiz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632417>
7. **Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study.** *J Thorac Dis* 2020; 12:1811-1823Wu F, Zhou Y, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642086>
8. **Recommendations from the German Respiratory Society for Pulmonary Rehabilitation in Patients with COVID-19.** *Pneumologie (Stuttgart, Germany)* 2020; Glöckl R, Buhr-Schinner H, Koczulla AR *et al.*
9. **Delayed pulmonary abscess following COVID-19 pneumonia: A case report.** *Respir Med Res* 2020; 78:100776Renaud-Picard B, Gallais F, Riou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623310>
10. **Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists.** *Virchows Arch.* 2020; Calabrese F, Pezzuto F, Fortarezza F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642842>

Renal disease (9 articles)

1. **Renal complications in COVID-19: A systematic review and meta-analysis.** *Ann. Med.* 2020:1-18Kunutsor SK, Laukkanen JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643418>
2. **Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.** *Clin Infect Dis* 2020; Oussalah A, Gleye S, Clerc Urmes I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623470>
3. **COVID-19 in Patients with Kidney Disease.** *Clin J Am Soc Nephrol* 2020; Ajaimy M, Melamed ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636199>
4. **Acute Renal Failure in Critically Ill COVID-19 Patients With a Focus on the Role of Renal Replacement Therapy: A Review of What We Know So Far.** *Cureus* 2020; 12:e8429Raza A, Estepa A, Chan V, Jafar MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642345>
5. **Authors' Reply.** *J Am Soc Nephrol* 2020; Batlle D, Soler MJ, Welling PA, Swaminathan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636207>
6. **Kidney Involvement in COVID-19: Need for Better Definitions.** *J Am Soc Nephrol* 2020; Delsante M, Rossi GM, Gandolfini I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646857>
7. **Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury.** *J Am Soc Nephrol* 2020; Kow CS, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639940>
8. **Results of a healthcare organization model for COVID-19 on hemodialysis in a tertiary hospital and its subsidized centers.** *Nefrologia* 2020; Sanchez-Perez P, Gonzalez-Calero P, Poma-Saavedra FH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622482>
9. **Suspension and resumption of kidney transplant programs during the COVID-19 pandemic: perspectives from patients, caregivers and potential living donors-a qualitative study.** *Transpl Int* 2020; Guha C, Tong A, Baumgart A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640048>

Reviews (50 articles)

1. **Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature.** *Adv Ther* 2020; Rahimi L, Malek M, Ismail-Beigi F, Khamseh ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632851>
2. **Road toward rapid-molecular point of care test to detect novel SARS-coronavirus 2019 (COVID-19): Review from updated literature.** *Allergol. Immunopathol. (Madr.)* 2020; Ahmad S, Ali N, Kausar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636083>
3. **Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection risk during elective peri-operative care: a narrative review.** *Anaesthesia* 2020; Schutzer-Weissmann J, Magee DJ, Farquhar-Smith P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652529>
4. **Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description.** *Brain* 2020; Hernandez-Fernandez F, Valencia HS, Barbella-Aponte RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645151>
5. **Cerebrovascular Disease in Patients with COVID-19: A Review of the Literature and Case Series.** *Case Rep. Neurol.* 2020; 12:199-209Reddy ST, Garg T, Shah C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647526>
6. **Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.** *Cell. Signal.* 2020:109706Chen X, Geiger JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629149>
7. **Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.** *Cells* 2020; 9Labo N, Ohnuki H, Tosato G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629875>
8. **COVID-19 in Patients with Kidney Disease.** *Clin J Am Soc Nephrol* 2020; Ajaimy M, Melamed ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636199>
9. **COVID-19 and diabetes: What have we learned so far?** *Clin Med (Lond)* 2020; Taher N, Huda MS, Chowdhury TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628128>
10. **The COVID-19 pandemic.** *Crit. Rev. Clin. Lab. Sci.* 2020:1-24Ciotti M, Ciccozzi M, Terrinoni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645276>
11. **A Review of Acute Myocardial Injury in Coronavirus Disease 2019.** *Cureus* 2020; 12:e8426B KA, Chaudhuri D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642342>
12. **The Psychological Impact of Epidemic and Pandemic Outbreaks on Healthcare Workers: Rapid Review of the Evidence.** *Curr Psychiatry Rep* 2020; 22:43Preti E, Di Mattei V, Perego G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651717>
13. **SARS-CoV-2 infection (COVID-19): What can we expect?** *Deutsche Medizinische Wochenschrift* 2020; 145:740-746Kern WV, Kern WV, Biever PM *et al.*
14. **Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events.** *Diabetes Metab Syndr* 2020; 14:1017-1025Nandy K, Salunke A, Pathak SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634716>
15. **Association of diabetes and hypertension with disease severity in covid-19 patients: a systematic literature review and exploratory meta-analysis.** *Diabetes Res Clin Pract* 2020:108295Parveen R, Sehar N, Bajpai R, Bharal Agarwal N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623032>
16. **Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.** *Diagn. Microbiol. Infect. Dis.* 2020; 98:115094Ortiz-Prado E, Simbana-Rivera K, Gomez-Barreno L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623267>
17. **The impact of ethnicity on clinical outcomes in COVID-19: A systematic review.** *EClinicalMedicine* 2020; 23:100404Pan D, Sze S, Minhas JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632416>
18. **Large vessel stroke and COVID-19: Case report and literature review.** *eNeurologicalSci* 2020; 20:100250Mahboob S, Boppana SH, Rose NB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632380>
19. **Basic Immunology may lead to translational therapeutic rationale:: SARS-CoV-2 and Rheumatic Diseases.** *Eur. J. Clin. Invest.* 2020:e13342Gremese E, Ferraccioli ES, Alivernini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645207>
20. **Transmission of SARS-CoV-2: an update of current literature.** *Eur J Clin Microbiol Infect Dis* 2020; Patel KP, Vunnam SR, Patel PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638221>
21. **Role of inflammatory markers in corona virus disease (COVID-19) patients: A review.** *Exp. Biol. Med. (Maywood)* 2020:1535370220939477Upadhyay J, Tiwari N, Ansari MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635752>
22. **Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.** *Immunol. Invest.* 2020:1-7Mansouri N, Marjani M, Tabarsi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633162>
23. **Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review.** *Indian J. Clin. Biochem.* 2020; 35:260-273Lingeswaran M, Goyal T, Ghosh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641873>
24. **COVID-19 dentistry-related aspects: a literature overview.** *Int. Dent. J.* 2020; Checchi V, Bellini P, Bencivenni D, Consolo U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623723>
25. **A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.** *Int J Antimicrob Agents* 2020:106078Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629115>
26. **COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.** *Int J Antimicrob Agents* 2020:106080Song Y, Zhang M, Yin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634603>
27. **The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review.** *Int J Infect Dis* 2020; Al-Sadeq DW, Nasrallah GK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623083>
28. **Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.** *Int J Infect Dis* 2020; Sun M, Xu Y, He H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634589>
29. **Cardiac manifestations in COVID-19 patients-A systematic review.** *J. Card. Surg.* 2020; Shafi AMA, Shaikh SA, Shirke MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652713>
30. **Frailty and COVID-19: A Systematic Scoping Review.** *J Clin Med* 2020; 9Maltese G, Corsonello A, Di Rosa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635468>
31. **Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.** *J Clin Med* 2020; 9Meini S, Pagotto A, Longo B *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629768>
32. **A review on histotechnology practices in COVID-19 pathology investigations.** *J Histotechnol* 2020;1-6Malloy S, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643596>
 33. **Systematic review of artificial intelligence techniques in the detection and classification of COVID-19 medical images in terms of evaluation and benchmarking: Taxonomy analysis, challenges, future solutions and methodological aspects.** *J Infect Public Health* 2020; Albahri OS, Zaidan AA, Albahri AS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646771>
 34. **Pregnancy and COVID-19: a systematic review of maternal, obstetric and neonatal outcomes.** *J Matern Fetal Neonatal Med* 2020;1-13Trocado V, Silvestre-Machado J, Azevedo L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635775>
 35. **Extra-pulmonary complications of COVID-19: a multi-system disease?** *J Med Virol* 2020; Zheng KI, Feng G, Liu WY *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648973>
 36. **Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).** *J Transl Med* 2020; 18:274Zhu RF, Gao YL, Robert SH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631442>
 37. **Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.** *JAMA* 2020; Wiersinga WJ, Rhodes A, Cheng AC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648899>
 38. **Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients.** *Med. Intensiva* 2020; Moreno G, Carbonell R, Bodi M, Rodriguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646669>
 39. **Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.** *Mol. Cell. Probes* 2020;101636Torabi R, Ranjbar R, Halaji M, Heiat M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634550>
 40. **Is Guillain-Barre syndrome triggered by SARS-CoV-2? Case report and literature review.** *Neurol Sci* 2020; Agosti E, Giorgianni A, D'Amore F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643136>
 41. **Molecular Aspects of COVID-19 Differential Pathogenesis.** *Pathogens* 2020; 9Rothan HA, Acharya A, Reid SP *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640525>
 42. **Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.** *Reprod. Biomed. Online* 2020; La Marca A, Capuzzo M, Paglia T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651106>
 43. **Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.** *Rev Med Virol* 2020:e2136Giovane RA, Rezai S, Cleland E, Henderson CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644275>
 44. **COVID-19 in Children: An Ample Review.** *Risk Manag. Healthc. Policy* 2020; 13:661-669Ciuca IM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636686>
 45. **Novel coronavirus pandemic: A clinical overview.** *S Afr Fam Pract (2004)* 2020; 62:e1-e5Kaswa R, Govender I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633997>
 46. **Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice.** *Tob Induc Dis* 2020; 18:58Grundy EJ, Suddek T, Filippidis FT *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641924>
 47. **Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?** *Transfus. Apher. Sci.* 2020:102858Garraud O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631501>
 48. **Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.** *Trop Med Infect Dis* 2020; 5Farooqi F, Dhawan N, Morgan R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635353>
 49. **The newly emerged COVID-19 disease: a systemic review.** *Virol J* 2020; 17:96Abebe EC, Dejenie TA, Shiferaw MY, Malik T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641059>
 50. **Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.** *Viruses* 2020; 12Santos J, Brierley S, Gandhi MJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629804>

Risk factors (65 articles)

1. **Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan, China.** *Aging (Albany NY)* 2020; 12Gao S, Jiang F, Jin W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651993>
2. **Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study.** *Aging (Albany NY)* 2020; 12:11245-11258Han Y, Zhang H, Mu S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633729>
3. **Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China.** *Aging (Albany NY)* 2020; 12Liu X, Zheng X, Liu B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628642>
4. **COVID-19 and air pollution: A dangerous association?** *Allergol. Immunopathol. (Madr.)* 2020; Urrutia-Pereira M, Mello-da-Silva CA, Sole D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636082>
5. **ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS.** *Am. J. Pathol.* 2020; Argyropoulos KV, Serrano A, Hu J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628931>
6. **DISEQUILIBRIUM BETWEEN THE CLASSIC RENIN-ANGIOTENSIN SYSTEM AND ITS OPPOSING ARM IN SARS-COV-2 RELATED LUNG INJURY.** *Am J Physiol Lung Cell Mol Physiol* 2020; Sarzani R, Giulietti F, Di Pentima C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639866>
7. **RV Infections in Asthmatics Increase ACE2 Expression and Cytokine Pathways Implicated in COVID-19.** *Am J Respir Crit Care Med* 2020; Chang EH, Willis AL, Romanoski CE *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649217>
8. **SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age.** *Amino Acids* 2020; Vuille-Dit-Bille RN, Liechty KW, Verrey F, Guglielmetti LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627059>
9. **A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity.** *Arch Pathol Lab Med* 2020; Aloisio E, Chibireva M, Serafini L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649222>

10. **Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.** *Cancers (Basel)* 2020; 12:Pinato DJ, Lee AJX, Biello F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650523>
11. **Development and Validation of a Nomogram for Assessing Survival in Patients with COVID-19 Pneumonia.** *Clin Infect Dis* 2020; Dong YM, Sun J, Li YX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649738>
12. **Predictors of progression from moderate to severe COVID-19: a retrospective cohort.** *Clin Microbiol Infect* 2020; Cheng B, Hu J, Zuo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622952>
13. **Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China.** *Crit Care* 2020; 24:394Xu J, Yang X, Yang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631393>
14. **Recent exposure to smoking and COVID-19.** *Crit Care Resusc* 2020; Landoni G, Moro M, Belletti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645763>
15. **Smoking in critically ill patients with COVID-19: the Australian experience.** *Crit Care Resusc* 2020; Plummer MP, Pellegrini B, Burrell AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634894>
16. **Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS.** *Cureus* 2020; 12:e8411Gumashta J, Gumashta R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626626>
17. **Angiotensin II Receptors - Impact for COVID-19 Severity.** *Dermatol Ther* 2020:e13989Aksoy H, Karadag AS, Wollina U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645228>
18. **Vitamin D deficiency in patients with diabetes and COVID-19 infection.** *Diabetes Metab Syndr* 2020; 14:1033-1035Singh SK, Jain R, Singh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640414>
19. **COVID-19 and ethnicity: A novel pathophysiological role for inflammation.** *Diabetes Metab Syndr* 2020; 14:1043-1051Vepa A, Bae JP, Ahmed F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640416>
20. **Risk Factors for Mortality among COVID-19 Patients.** *Diabetes Res Clin Pract* 2020:108293Albitar O, Ballouze R, Ping Ooi J, Maisharah Sheikh Ghadzi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623035>
21. **Association of diabetes and hypertension with disease severity in covid-19 patients: a systematic literature review and exploratory meta-analysis.** *Diabetes Res Clin Pract* 2020:108295Parveen R, Sehar N, Bajpai R, Bharal Agarwal N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623032>
22. **The Impact of COVID-19 on People with Diabetes in Brazil.** *Diabetes Res Clin Pract* 2020:108304Thomaz Ugliara Barone M, Bega Harnik S, Vieira de Luca P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623040>
23. **Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease.** *Diabetol. Metab. Syndr.* 2020; 12:57Rastad H, Karim H, Ejtahed HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641974>
24. **Hyperglycaemia on admission to hospital and COVID-19.** *Diabetologia* 2020; Sardu C, D'Onofrio N, Balestrieri ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632527>
25. **Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019.** *EBioMedicine* 2020; 57:102880Xiao LS, Zhang WF, Gong MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645614>
26. **The impact of ethnicity on clinical outcomes in COVID-19: A systematic review.** *EClinicalMedicine* 2020; 23:100404Pan D, Sze S, Minhas JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632416>
27. **Endocrine significance of SARS-CoV-2's reliance on ACE2.** *Endocrinology* 2020; Lazartigues E, Qadir MMF, Mauvais-Jarvis F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652001>
28. **Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis.** *Eur Radiol* 2020; Francone M, Iafrate F, Masci GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623505>
29. **Predictor of poor prognosis of COVID-19 patients----liver injury.** *Expert Rev. Gastroenterol. Hepatol.* 2020; Fu T, Deng M, Wang X, Yang F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643980>
30. **Leucocyte Subsets Effectively Predict the Clinical Outcome of Patients With COVID-19 Pneumonia: A Retrospective Case-Control Study.** *Front Public Health* 2020; 8:299Gan J, Li J, Li S, Yang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626680>
31. **Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).** *Hepatol Int* 2020; Sarin SK, Choudhury A, Lau GK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623632>
32. **Transmissibility of COVID-19 in 11 major cities in China and its association with temperature and humidity in Beijing, Shanghai, Guangzhou, and Chengdu.** *Infect Dis Poverty* 2020; 9:87Guo XJ, Zhang H, Zeng YP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650838>
33. **Prevalence and Predictors of Anxiety and Depression Symptoms during the COVID-19 Pandemic and Compliance with Precautionary Measures: Age and Sex Matter.** *Int J Environ Res Public Health* 2020; 17Solomou I, Constantinidou F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650522>
34. **Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID-19.** *J Am Geriatr Soc* 2020; Brouns SH, Bruggemann R, Linkens A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633418>
35. **Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.** *J Autoimmun* 2020:102512Morrison AR, Johnson JM, Griebe KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646770>
36. **Nicotine and smoking in the COVID-19 era.** *J Cardiovasc Thorac Res* 2020; 12:136-139Tajili A, Ghaffari S, Pourafkari L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32626554>
37. **Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2.** *J Cell Mol Med* 2020; Li Y, Xu Q, Ma L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639084>
38. **Frailty and COVID-19: A Systematic Scoping Review.** *J Clin Med* 2020; 9Maltese G, Corsonello A, Di Rosa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635468>
39. **Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm.** *J Clin Med* 2020; 9Vinciguerra M, Romiti S, Fattouch K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635302>
40. **The Effect of the COVID-19 Pandemic on Smoking Cessation Success.** *J. Community Health* 2020; Kayhan Tetik B, Gedik Tekinemre I, Tas S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643078>
41. **The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19.** *J. Diabetes* 2020; Xu Z, Wang Z, Wang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638507>

42. **Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes.** *J. Diabetes Complications* 2020;107666Zhang Q, Wei Y, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636061>
43. **A Comparison of Mortality-related Risk Factors of COVID-19, SARS, and MERS: A Systematic Review and Meta-analysis.** *J Infect* 2020; Lu L, Zhong W, Bian Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634459>
44. **The Ambient Ozone and COVID-19 Transmissibility in China: A Data-Driven Ecological Study of 154 Cities.** *J Infect* 2020; Ran J, Zhao S, Han L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652165>
45. **Prevalence and predictive value of hypocalcemia in severe COVID-19 patients.** *J Infect Public Health* 2020; Liu J, Han P, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622796>
46. **The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data.** *J Korean Med Sci* 2020; 35:e243Kim DW, Byeon KH, Kim J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627443>
47. **Early-stage predictors of the acute phase duration in uncomplicated COVID-19 pneumonia.** *J Med Virol* 2020; Carallo C, Pugliese F, Tripolino C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644215>
48. **Obesity and Higher Risk for Severe Complications of Covid-19: What to do when the two pandemics meet.** *J. Popul. Ther. Clin. Pharmacol.* 2020; 27:e31-e36Valerio A, Nisoli E, Rossi AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650354>
49. **Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Zhang Y, Cao W, Jiang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648093>
50. **Double-quencher probes improve detection sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a reverse-transcription polymerase chain reaction (RT-PCR) assay.** *J. Virol. Methods* 2020:113926Hirotsu Y, Mochizuki H, Omata M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650037>
51. **Development and Validation of a Prognostic Nomogram Based on Clinical and CT Features for Adverse Outcome Prediction in Patients with COVID-19.** *Korean J Radiol* 2020; Zheng Y, Xiao A, Yu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643334>
52. **Hematological manifestations of COVID-19.** *Leuk. Lymphoma* 2020:1-9Mina A, Besien KV, Platanius LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643489>
53. **Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors.** *Med Clin (Barc)* 2020; Golpe R, Perez-de-Llano LA, Dacal D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651067>
54. **"We assume that there is a protective factor!": COVID-19 hits HIV patients mostly only mildly.** *MMW-Fortschritte der Medizin* 2020; 162:12-13.
55. **Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.** *Neurol Sci* 2020; Hwang JM, Kim JH, Park JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643133>
56. **SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.** *Pathogens* 2020; 9Kalra RS, Tomar D, Meena AS, Kandimalla R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645974>
57. **Cancer Patients Have a Higher Risk Regarding COVID-19 - and Vice Versa?** *Pharmaceuticals (Basel)* 2020; 13Geisslinger F, Vollmar AM, Bartel K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640723>
58. **Association of Padua prediction score with in-hospital prognosis in COVID-19 patients.** *QJM* 2020; Zeng DX, Xu JL, Mao QX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652021>
59. **Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score-matching analysis.** *Respir Res* 2020; 21:172Yang Q, Zhou Y, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631365>
60. **Snowballing transmission of COVID-19 (SARS-CoV-2) through wastewater: Any sustainable preventive measures to curtail the scourge in low-income countries?** *Sci Total Environ* 2020; 742:140680Adelodun B, Ajibade FO, Ibrahim RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629273>
61. **Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis.** *Ther. Adv. Chronic Dis.* 2020; 11:2040622320935765Farsalinos K, Barbouni A, Poulas K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637059>
62. **Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19.** *Theranostics* 2020; 10:7231-7244Wu Q, Wang S, Li L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641989>
63. **Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice.** *Tob Induc Dis* 2020; 18:58Grundy EJ, Suddek T, Filippidis FT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641924>
64. **Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.** *Toxicol Rep* 2020; 7:768-771Nasi A, McArdle S, Gaudernack G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632359>
65. **The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide.** *Virus Res.* 2020:198089Yamasaki Y, Ooka S, Tsuchida T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629085>

Safety (17 articles)

1. **Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.** *Br. J. Clin. Pharmacol.* 2020; Gatti M, Fusaroli M, Caraceni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639062>
2. **Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).** *Cancer Treat. Rev.* 2020; 88:102063Slimano F, Baudouin A, Zerbit J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623296>
3. **Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of**

- France. *Clin Infect Dis* 2020; Oussalah A, Gleye S, Clerc Urmes I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623470>
4. **Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.** *Eur J Intern Med* 2020; Afra TP, Nampoothiri RV, Razmi TM, Hafi NAB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651040>
 5. **Covid-19 treatment-induced neuropsychiatric adverse effects.** *Gen. Hosp. Psychiatry* 2020; Garcia CAC, Sanchez EBA, Huerta DH, Gomez-Arnau J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636036>
 6. **Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.** *Heart Rhythm* 2020; Offerhaus JA, Wilde AAM, Remme CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622993>
 7. **Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.** *Ir. J. Med. Sci.* 2020; Carron J, Sharif Z, Hussein H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627127>
 8. **Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.** *J Am Acad Dermatol* 2020; Lipner SR, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652194>
 9. **Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury.** *J Am Soc Nephrol* 2020; Kow CS, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639940>
 10. **Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes.** *J. Diabetes Complications* 2020;107666Zhang Q, Wei Y, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636061>
 11. **SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS.** *J Infect* 2020; Rossotti R, Travi G, Ughi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652164>
 12. **Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.** *J Med Virol* 2020; Gomez-Mayordomo V, Montero-Escribano P, Matias-Guiu JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644205>
 13. **The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.** *Neth. Heart J* 2020; Sinkeler FS, Berger FA, Muntinga HJ, Jansen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648153>
 14. **SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.** *Pathogens* 2020; 9Kalra RS, Tomar D, Meena AS, Kandimalla R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645974>
 15. **NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection.** *Therapie* 2020; Cumhuri Cure M, Kucuk A, Cure E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636031>
 16. **SARS-CoV2 and immunosuppression: a double-edged sword.** *Transpl Infect Dis* 2020:e13404Lai Q, Spoletini G, Bianco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639598>
 17. **Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.** *Travel Med Infect Dis* 2020:101812Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645478>

Treatment options (88 articles)

1. **Is Inhaled Furosemide a Potential Therapeutic for COVID-19?** *Am. J. Med. Sci.* 2020; Brennecke A, Villar L, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622469>
2. **A severe refractory COVID-19 patient responding to convalescent plasma; A case series.** *Ann Med Surg (Lond)* 2020; 56:125-127Abdullah HM, Hama-Ali HH, Ahmed SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637086>
3. **Could Ergothioneine Aid in the Treatment of Coronavirus Patients?** *Antioxidants (Basel)* 2020; 9Chead IK, Halliwell B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646061>
4. **Exploring the acceptability of controlled human infection with SARSCoV2-a public consultation.** *BMC Med* 2020; 18:209Gbesemete D, Barker M, Lawrence WT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635912>
5. **Potential role of IL-17 blocking agents in the treatment of severe COVID-19?** *Br. J. Clin. Pharmacol.* 2020; Bulat V, Situm M, Azdajic MD, Likic R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627226>
6. **Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.** *Br. J. Clin. Pharmacol.* 2020; Gatti M, Fusaroli M, Caraceni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639062>
7. **Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.** *Cell. Signal.* 2020:109706Chen X, Geiger JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629149>
8. **Canonical and Noncanonical Autophagy as Potential Targets for COVID-19.** *Cells* 2020; 9Bello-Perez M, Sola I, Novoa B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635598>
9. **In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.** *Chin J Integr Med* 2020; 26:527-532Gao LQ, Xu J, Chen SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632717>
10. **The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing ICU capacity.** *Clin Infect Dis* 2020; Nichols BE, Jamieson L, Zhang SRC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628744>
11. **Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.** *Clin Infect Dis* 2020; Oussalah A, Gleye S, Clerc Urmes I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623470>
12. **Tocilizumab for treatment of mechanically ventilated patients with COVID-19.** *Clin Infect Dis* 2020; Somers EC, Eschenauer GA, Troost JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651997>
13. **Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.** *Comput. Biol. Chem.* 2020; 88:107325Jimenez-Alberto A, Ribas-Aparicio RM, Aparicio-Ozores G, Castelan-Vega JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623357>

14. **Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.** *Crit Rev Anal Chem* 2020;1-16Saka C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628049>
15. **Packed Red Blood Cell Transfusion as a Potential Treatment Option in COVID-19 Patients With Hypoxemic Respiratory Failure: A Case Report.** *Cureus* 2020; 12:e8398Ejigu T, Patel N, Sharma A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637278>
16. **Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.** *Curr Drug Metab* 2020; Yao X, Hou Z, Cui C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651961>
17. **The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.** *Curr. Pharm. Des.* 2020; Martinez GP, Zabaleta ME, Di Giulio C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634079>
18. **Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.** *Curr. Stem Cell Res. Ther.* 2020; Richard SA, Kampo S, Sackey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628591>
19. **Therapeutic targets and computational approaches on drug development for COVID-19.** *Curr. Top. Med. Chem.* 2020; Shanmugam A, Muralidharan N, Velmurugan D, Gromiha MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648845>
20. **The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.** *Cytokine Growth Factor Rev.* 2020; Goker Bagca B, Biray Avci C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636055>
21. **Remdesivir for patients with COVID-19.** *Internist (Berl.)* 2020; Augustin M, Hallek M, Nitschmann S.
22. **Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.** *Drug Dev Res* 2020; Sohag AAM, Hannan MA, Rahman S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632960>
23. **SGLT2 inhibition and COVID-19: The road not taken.** *Eur. J. Clin. Invest.* 2020:e13339Das L, Dutta P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648935>
24. **Basic Immunology may lead to translational therapeutic rationale:: SARS-CoV-2 and Rheumatic Diseases.** *Eur. J. Clin. Invest.* 2020:e13342Gremese E, Ferraccioli ES, Alivernini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645207>
25. **Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.** *Eur J Intern Med* 2020; Afra TP, Nampoothiri RV, Razmi TM, Hafi NAB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651040>
26. **Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus.** *Eur. J. Pharmacol.* 2020;173348Omolo CA, Soni N, Fasiku VO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634438>
27. **Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true?** *Eur Radiol Exp* 2020; 4:42Zaitoun MMA, Basha MAA, Elmokadem AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632766>
28. **Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine; from HIV-1 infection to COVID-19.** *Expert Rev. Anti Infect. Ther.* 2020; Naghipour S, Ghodousi M, Rahsepar S, Elyasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631083>
29. **Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).** *Front. Immunol.* 2020; 11:1451Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636851>
30. **Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.** *Front. Pharmacol.* 2020; 11:959Belladonna ML, Orabona C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636755>
31. **The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease.** *Front. Physiol.* 2020; 11:752Szabo Z, Marosvolgyi T, Szabo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636763>
32. **Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.** *Future Med. Chem.* 2020; Fan S, Xiao D, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32638628>
33. **Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.** *Heart Rhythm* 2020; Offerhaus JA, Wilde AAM, Remme CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622993>
34. **Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.** *Immunol. Invest.* 2020;1-7Mansouri N, Marjani M, Tabarsi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633162>
35. **Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.** *Indian J. Clin. Biochem.* 2020; 35:274-284Pal A, Pawar A, Goswami K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641874>
36. **That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.** *Infect Dis Ther* 2020; Davis MR, McCreary EK, Pogue JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651941>
37. **Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.** *Infection* 2020; Cingolani A, Tummo ML, Montemurro G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642806>
38. **An update on antiviral antibody-based biopharmaceuticals.** *Int Immunopharmacol* 2020; 86:106760Ahangarzadeh S, Payandeh Z, Arezumand R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645633>
39. **Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.** *Int Immunopharmacol* 2020; 86:106749Zhang X, Zhang Y, Qiao W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645632>
40. **Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.** *Int J Antimicrob Agents* 2020:106077Bani-Sadr F, Hentzien M, Pascard M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634602>
41. **A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.** *Int J Antimicrob Agents* 2020:106078Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629115>
42. **COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.** *Int J Antimicrob Agents* 2020:106080Song Y, Zhang M, Yin L *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634603>
43. **Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.** *Int J Infect Dis* 2020; Arshad S, Kilgore P, Chaudhry ZS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32623082>
 44. **An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.** *Int J Infect Dis* 2020; Lee TC, MacKenzie LJ, McDonald EG, Tong SYC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32623080>
 45. **Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.** *Int J Infect Dis* 2020; Sun M, Xu Y, He H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32634589>
 46. **Putative Roles for Peptidylarginine Deiminases in COVID-19.** *Int J Mol Sci* 2020; 21 Arisan ED, Uysal-Onganer P, Lange S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629995>
 47. **Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.** *Ir. J. Med. Sci.* 2020; Carron J, Sharif Z, Hussein H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627127>
 48. **Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.** *J Am Acad Dermatol* 2020; Lipner SR, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652194>
 49. **Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy.** *J Am Heart Assoc* 2020:e016948 Sardou C, Maggi P, Messina V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633594>
 50. **Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.** *J Autoimmun* 2020:102512 Morrison AR, Johnson JM, Griebel KM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32646770>
 51. **Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.** *J Biomol Struct Dyn* 2020:1-15 Al-Sehemi AG, Pannipara M, Parulekar RS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32643550>
 52. **Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.** *J Biomol Struct Dyn* 2020:1-13 Ibrahim MAA, Abdeljawad KAA, Abdelrahman AHM, Hegazy MF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32643529>
 53. **Convalescent plasma therapy in patients with COVID-19.** *J. Clin. Apher.* 2020; Yigenoglu TN, Hacibekiroglu T, Berber I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643200>
 54. **Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.** *J Clin Med* 2020; 9 Meini S, Pagotto A, Longo B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32629768>
 55. **Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.** *J. Drug Target.* 2020:1-46 Alvi MM, Sivasankaran S, Singh M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32643436>
 56. **SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS.** *J Infect* 2020; Rossotti R, Travi G, Ughi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652164>
 57. **Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.** *J Korean Med Sci* 2020; 35:e2391m JH, Nahm CH, Baek JH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32627442>
 58. **BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.** *J. Leukoc. Biol.* 2020; McGee MC, August A, Huang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32640487>
 59. **Tocilizumab in patients with severe COVID-19: A single-center observational analysis.** *J Med Virol* 2020; Knorr JP, Colomy V, Mauriello CM, Ha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628003>
 60. **RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.** *J Med Virol* 2020; Wang Y, Anirudhan V, Du R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633831>
 61. **Covid-19: A systemic disease treated with a wide-ranging approach: A case report.** *J. Popul. Ther. Clin. Pharmacol.* 2020; 27:e26-e30 Massabeti R, Cipriani MS, Valenti I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32650356>
 62. **Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.** *J. Popul. Ther. Clin. Pharmacol.* 2020; 27:e14-e25 Valentini M, Zmerly H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32650355>
 63. **Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.** *JAMA Netw Open* 2020; 3:e2013136 Deffereos SG, Giannopoulos G, Vrachatis DA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32579195>
 64. **Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?** *JAMA Netw Open* 2020; 3:e2013556 Rabbani AB, Parikh RV, Rafique AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579190>
 65. **Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.** *Kidney Int* 2020; Gade AR, Alavala H, Allam SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650019>
 66. **Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.** *Microorganisms* 2020; 8 Cavagna L, Seminari E, Zanframundo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629788>
 67. **Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.** *Mol. Cell. Probes* 2020:101636 Torabi R, Ranjbar R, Halaji M, Heiat M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32634550>
 68. **The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.** *Neth. Heart J.* 2020; Sinkeler FS, Berger FA, Muntinga HJ, Jansen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648153>
 69. **SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.** *Pathogens* 2020; 9 Kalra RS, Tomar D, Meena AS, Kandimalla R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645974>
 70. **Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.** *Pharmaceuticals (Basel)* 2020; 13 Palmeira A, Sousa E, Koseler A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32630514>

71. **Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.** *Proc Natl Acad Sci U S A* 2020; Dawadi S, Simmons N, Miklossy G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641511>
72. **BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).** *Proc Natl Acad Sci U S A* 2020; Escobar LE, Molina-Cruz A, Barillas-Mury C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32647056>
73. **Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.** *Rev Med Virol* 2020:e2136Giovane RA, Rezai S, Cleland E, Henderson CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644275>
74. **Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.** *Rev Med Virol* 2020; Keam S, Megawati D, Patel SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648313>
75. **COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?** *Tohoku J. Exp. Med.* 2020; 251:175-181Razzaque MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641644>
76. **Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.** *Toxicol Rep* 2020; 7:768-771Nasi A, McArdle S, Gaudernack G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632359>
77. **Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?** *Transfus. Apher. Sci.* 2020:102858Garraud O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631501>
78. **Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.** *Transfus. Apher. Sci.* 2020:102855Yigenoglu TN, Ulas T, Dal MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636114>
79. **Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.** *Transpl Infect Dis* 2020:e13401Saraceni F, Scortechini I, Mancini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629531>
80. **Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.** *Travel Med Infect Dis* 2020:101812Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645478>
81. **Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.** *Trials* 2020; 21:631Duska F, Waldauf P, Halacova M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641163>
82. **Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:635Gopel S, Bethge W, Martus P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650818>
83. **Repurposed immunomodulatory drugs for Covid-19 in pre-ICU patients - mulTi-Arm Therapeutic study in pre-ICU patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:626Kulkarni S, Fisk M, Kostapanos M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641154>
84. **Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.** *Trials* 2020; 21:622Liu X, Chen H, Shang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641091>
85. **Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.** *Trop Med Infect Dis* 2020; 5Farooqi F, Dhawan N, Morgan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635353>
86. **The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide.** *Virus Res.* 2020:198089Yamasaki Y, Ooka S, Tsuchida T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629085>
87. **Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.** *Viruses* 2020; 12Santos J, Brierley S, Gandhi MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32629804>
88. **[Exploration of fire needling therapy on coronavirus disease 2019].** *Zhongguo Zhen Jiu* 2020; 40:693-696Lin SY, Zhang YC, Wei YZ, Lin GH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3264838>

Trials (15 articles)

1. **Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study.** *Aging (Albany NY)* 2020; 12:11245-11258Han Y, Zhang H, Mu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633729>
2. **COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.** *Am J Respir Crit Care Med* 2020; Mathioudakis AG, Fally M, Hashad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634026>
3. **Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study.** *Clin Infect Dis* 2020; Kragholm K, Andersen MP, Gerds TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634827>
4. **Predictors of progression from moderate to severe COVID-19: a retrospective cohort.** *Clin Microbiol Infect* 2020; Cheng B, Hu J, Zuo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622952>
5. **Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.** *Int J Infect Dis* 2020; Arshad S, Kilgore P, Chaudhry ZS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623082>
6. **An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.** *Int J Infect Dis* 2020; Lee TC, MacKenzie LJ, McDonald EG, Tong SYC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623080>
7. **The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data.** *J Korean Med Sci* 2020; 35:e243Kim DW, Byeon KH, Kim J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627443>
8. **Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study.** *J Thorac Dis* 2020; 12:1811-1823Wu F, Zhou Y, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32642086>

9. **Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).** *J Transl Med* 2020; 18:274Zhu RF, Gao YL, Robert SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631442>
10. **Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score-matching analysis.** *Respir Res* 2020; 21:172Yang Q, Zhou Y, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631365>
11. **Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:614Beigmohammadi MT, Bitarafan S, Hoseindokht A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32631405>
12. **Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.** *Trials* 2020; 21:631Duska F, Waldauf P, Halacova M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641163>
13. **Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:635Gopel S, Bethge W, Martus P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650818>
14. **Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:626Kulkarni S, Fisk M, Kostapanos M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641154>
15. **Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.** *Trials* 2020; 21:622Liu X, Chen H, Shang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641091>

Vaccines (7 articles)

1. **A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.** *Cell* 2020; Dai L, Zheng T, Xu K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645327>
2. **Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.** *Cell* 2020; Sun J, Zhuang Z, Zheng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643603>
3. **Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.** *Clin Infect Dis* 2020; Nguyen LC, Bakerlee CW, McKelvey TG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628748>
4. **A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.** *Front. Pharmacol.* 2020; 11:937Funk CD, Laferriere C, Ardakani A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32636754>
5. **Do Not Minimize the Impact of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.** *J Infect Dis* 2020; Schlom J, Donahue RN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651586>
6. **Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.** *J Microbiol Biotechnol* 2020; Kim KD, Hwang I, Ku KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627758>
7. **Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.** *Vaccine* 2020; Ren W, Sun H, Gao GF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32651113>

Women – pregnancy (31 articles)

1. **Multi-centre Spanish study found no incidences of viral transmission in infants born to mothers with COVID-19.** *Acta Paediatr* 2020; Marin Gabriel MA, Cuadrado I, Alvarez Fernandez B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32649784>
2. **Setting realistic goals for feeding infants when their mothers have suspected or confirmed COVID-19.** *Acta Paediatr* 2020; Mosalli R, Paes B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628783>
3. **Pregnancy with Covid-19: Management considerations for care of severe and critically ill cases.** *Am. J. Reprod. Immunol.* 2020:e13299Chen L, Jiang H, Zhao Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623810>
4. **Preparing maternity for COVID-19: A translational simulation approach.** *Aust N Z J Obstet Gynaecol* 2020; Lowe B, De Araujo V, Haughton H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32648254>
5. **Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: A prospective cohort study.** *Bjog* 2020; Prabhu M, Cagino K, Matthews KC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633022>
6. **Negative Transmission of SARS-CoV-2 to Hand-Expressed Colostrum from SARS-CoV-2-Positive Mothers.** *Breastfeed. Med.* 2020; Marin Gabriel MA, Malalana Martinez AM, Marin Martinez ME, Anel Pedroche J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644841>
7. **Possible formation of pulmonary microthrombi in the early puerperium of pregnant women critically ill with COVID-19: Two case reports.** *Case Rep Womens Health* 2020; 27:e00237Tutiya CT, Sialyls MM, Kondo MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32637327>
8. **Distinct clinical characteristics and risk factors for mortality in female COVID-19 inpatients: a sex-stratified large-scale cohort study in Wuhan, China.** *Clin Infect Dis* 2020; Chen J, Bai H, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634830>
9. **Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study.** *Clin Infect Dis* 2020; Kragholm K, Andersen MP, Gerds TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32634827>
10. **Screening of Mothers in a COVID-19 Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers from Rostock by ELISA and Confirmation by Immunofluorescence.** *Deutsche medizinische Wochenschrift (1946)* 2020; Reisinger EC, von Possel R, Warnke P *et al.*

11. **Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain.** EClinicalMedicine 2020; 23:100407San-Juan R, Barbero P, Fernandez-Ruiz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32632417>
12. **Retrospective Description of Pregnant Women Infected with Severe Acute Respiratory Syndrome Coronavirus 2, France.** Emerg Infect Dis 2020; 26:Vivanti AJ, Mattern J, Vauloup-Fellous C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633712>
13. **Fetal heart rate changes on the cardiocotograph trace secondary to maternal COVID-19 infection.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 252:286-293Gracia-Perez-Bonfils A, Martinez-Perez O, Llubra E, Chandraharan E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32645644>
14. **Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!** Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 252:300-302Rozenberg S, Reverce P, Fastrez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32650189>
15. **SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle.** Fertil. Steril. 2020; Henarejos-Castillo I, Sebastian-Leon P, Devesa-Peiro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641214>
16. **Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues.** Fertil. Steril. 2020; 114:33-43Stanley KE, Thomas E, Leaver M, Wells D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32622411>
17. **A call for a gender-responsive, intersectional approach to address COVID-19.** Glob Public Health 2020:1-9Ryan NE, El Ayadi AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633628>
18. **Performing gynecologic cancer surgery during the COVID-19 pandemic in Turkey: A multicenter retrospective observational study.** Int J Gynaecol Obstet 2020; Dursun P, Dervisoglu H, Daggez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623717>
19. **The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting.** Int J Gynaecol Obstet 2020; Takemoto MLS, Menezes MO, Andreucci CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32644220>
20. **Association between social support and anxiety among pregnant women in the third trimester during the coronavirus disease 2019 (COVID-19) epidemic in Qingdao, China: The mediating effect of risk perception.** Int J Soc Psychiatry 2020:20764020941567Yue C, Liu C, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643510>
21. **For the life after COVID-19 pandemic - A gynecologist's call to action.** J Gynecol Obstet Hum Reprod 2020:101850Hosapatna Basavarajappa D, Saha PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32623066>
22. **Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state.** J Matern Fetal Neonatal Med 2020:1-9Makatsariya AD, Slukhanchuk EV, Bitsadze VO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32627622>
23. **Pregnancy and COVID-19: a systematic review of maternal, obstetric and neonatal outcomes.** J Matern Fetal Neonatal Med 2020:1-13Trocado V, Silvestre-Machado J, Azevedo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32635775>
24. **Thrombocytopenia in pregnancy: the importance of differential diagnosis during the COVID-19 pandemic.** J Matern Fetal Neonatal Med 2020:1-3Zitiello A, Grant GE, Ben Ali N, Feki A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643469>
25. **The "scar" of a pandemic: cumulative incidence of COVID-19 during the first trimester of pregnancy.** J Med Virol 2020; Cosma S, Borella F, Carosso A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32633869>
26. **Changes in RT-PCR test results and symptoms during the menstrual cycle of female individuals infected with SARS-CoV-2: report of two cases.** J Med Virol 2020; Zheng H, Tan J, Ma K, Meng W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32639581>
27. **Prenatal screening diagnosis and management in the era of coronavirus: the Sardinian experience.** J. Perinat. Med. 2020; Monni G, Corda V, Iuculano A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32628637>
28. Journal fur Gynakologische Endokrinologie 2020; 30:37-38Fischl F.
29. **The experience of women infected by the COVID-19 during pregnancy in Brazil: a qualitative study protocol.** Reprod Health 2020; 17:108Freitas-Jesus JV, Rodrigues L, Surita FG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32641133>
30. **[The impact of Covid-19 pandemic on breastfeeding and birth care. The importance of recovering good practices.].** Rev. Esp. Salud Publica 2020; 94Lalaguna Mallada P, Diaz-Gomez NM, Costa Romero M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32643708>
31. **[Infection by SARS-CoV-2 in pregnancy and possibility of transmission to neonates: A systematic revision].** Semergen 2020; Cabero-Perez MJ, Gomez-Acebo I, Dierssen-Sotos T, Llorca J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32646729>

to subscribe click [here](#)
